

## CINS PUBLICATIONS

### PHD THESES

---

#### NUMBER OF PHD THESES

CINS I: 11

CINS II: 27

---

#### CINS I

**Bodil Aggernæs**, CNSR: Information processing in schizophrenia: A longitudinal study of first-episode, antipsychotic-naïve schizophrenia patients. University of Copenhagen, Faculty of Health Sciences. Defended October 14<sup>th</sup>, 2009.

**Hans Rasmussen**, CNSR and CIMBI: Imaging serotonin 2A receptors in schizophrenia patients before and after first antipsychotic treatment. University of Copenhagen, Faculty of Health Sciences. Defended October 18<sup>th</sup>, 2009.

**Lone Baandrup**, CNSR: Antipsychotic polypharmacy: Exploring the gap between evidence and practice. University of Copenhagen, Faculty of Health Sciences. Defended January 8<sup>th</sup>, 2010.

**Bjørn H. Ebdrup**, CNSR and DRCMR: Structural Brain Changes in Antipsychotic-Naïve First-Episode Schizophrenia Patients Before and After Six Months of Antipsychotic Monotherapy. University of Copenhagen, Faculty of Health Sciences. Defended February 26<sup>th</sup>, 2010.

**Rune Andersen**, CNSR: Cognition in First Episode Schizophrenia: Core Deficits and Effects of Antipsychotics. University of Copenhagen, Faculty of Social Sciences. Defended July 2, 2010.

**Brian V Broberg**, CNSR, DRCMR, H. Lundbeck, and the Graduate School of in Vivo Pharmacology, Faculty of Health Sciences, University of Copenhagen: Animal disease models of schizophrenia. Phenotypical characterization of two treatment paradigms involving phencyclidine – sub-chronic and early postnatal treatment. This thesis was not supported by CINS but Birte Glenthøj (CINS/CNSR) was faculty supervisor and Olaf Paulson (CINS/DRCMR) was co-supervisor together with Christina K Olsen and Niels Plath (H. Lundbeck). Defended July 9, 2010.

**Nikolaj Bak**, CNSR, FIUNIT: Concurrent fMRI and EEG Source Localization of Sensory Gating: evidence for hippocampal and insular involvement in deficient gating in schizophrenia. Supported by LUCENS as well as CINS. Defended October 7, 2011.

**Trine B Hammer**, CNSR: Sensorimotor Gating in Schizophrenia: Long term outcome and structural brain correlates in (initially) antipsychotic-naïve first-episode patients.

University of Copenhagen, Faculty of Health Sciences.  
Defended November 10, 2011.

**Mette Ødegaard Nielsen**, CNSR: Reward processing in Schizophrenia before and after antipsychotic monotherapy.

University of Copenhagen, Faculty of Health Sciences.  
Defended October 11, 2012.

**Ayna Baladi Nejad**, CNSR, DRMR: Longitudinal MRI study of functional brain connectivity during a working memory task in antipsychotic-naïve, first-episode schizophrenia patients

University of Copenhagen, Faculty of Health Sciences.  
Defended January 25, 2013.

**Gitte Falcher Madsen**, CNSR, CINS, Mental Health Services in Region of Southern Denmark: Sensory gating in Autism Spectrum Disorders. The Search for subgroups.

Defended October 9, 2013.

---

## CINS II

**Dorte Nordholm**, CINS, PC Copenhagen/Bispebjerg: Stress and oxidative stress during early phases of psychosis.

University of Copenhagen, Faculty of Health Sciences.  
Defended February 28, 2014.

**Signe Wegmann Düring Clausen**, CNSR, CINS: Effect of treatment with a dopamine D2 blocker on early information processing: A longitudinal study of antipsychotic-naïve first-episode schizophrenia patients.

University of Copenhagen, Faculty of Health Sciences.  
Defended October 4, 2014.

**Louise Witten**, CNSR, CINS, H. Lundbeck: Cross-species identification and verification of psychophysiological parameters of early information processing: *focus on schizophrenia*.

University of Copenhagen, Faculty of Health Sciences.  
PHD Thesis defended October 26, 2014.

**Sanne Wulff**, CNSR, CINS: The Connection between Dopamine D<sub>2</sub> Activity, Reward Disturbances and Psychopathology in Antipsychotic-Naïve First-Episode Patients with Schizophrenia.

University of Copenhagen, Faculty of Health Sciences.  
Defended February 16, 2015.

**Maria Høj Jensen**, CNSR, CINS: The Cognitive Reserve Hypothesis of Schizophrenia.

University of Copenhagen, Faculty of Health Sciences.  
Defended May 28, 2015.

**Rikke Hilker**, CNSR, CINS: The Heritability of schizophrenia spectrum disorders; A Danish Twin Register Study.

University of Copenhagen, Faculty of Health Sciences.  
Defended June 10, 2015.

**Jacob Rydkjær**, CNSR, CINS: Neurophysiological biomarkers in young adolescents with first episode psychosis: A comparison with ADHD.  
University of Copenhagen, Faculty of Health Sciences.  
Defended October 30, 2015.

**Henrik Nørbak-Emig**, CNSR, CINS: Frontal dopamine D<sub>2/3</sub> receptors and brain structure in antipsychotic-naïve schizophrenia patients before and after their first antipsychotic treatment.  
P University of Copenhagen, Faculty of Health Sciences.  
Defended August 23, 2016.

**Simon Anhøj**, CNSR, CINS: Intrinsic Connectivity in First-Episode Schizophrenia.  
University of Copenhagen, Faculty of Health Sciences.  
Defended August 30, 2016.

**Louise Birkedal Glenthøj**, Research Unit, Mental Health Center Copenhagen & CINS: Targeting functioning in patients at ultra-high risk for psychosis: Baseline findings from the FOCUS trial.  
University of Copenhagen, Faculty of Health Sciences.  
Defended January 16, 2017.

**Ishøy PL**, CNSR, CINS: GLP-1 Receptor Agonist Treatment in Schizophrenia Patients with Obesity.  
University of Copenhagen, Faculty of Health Sciences.  
Defended May 3, 2017.

**Krakauer K**, Research Unit, Mental Health Center Copenhagen & CINS: Cerebral white matter changes in individuals at ultra high-risk for psychosis.  
University of Copenhagen, Faculty of Health Sciences.  
Defended September 27, 2017.

**Bojesen KB**, CNSR, CINS: Glutamate and GABA levels in patients with antipsychotic-naïve schizophrenia and associations with cognitive deficits and treatment outcome.  
University of Copenhagen, Faculty of Health Sciences.  
Defended June 11, 2018.

**Legind CS**, CNSR, CINS: Heritability and correlation to schizophrenia spectrum disorder of cerebral glutamate levels and perfusion – A register-based magnetic resonance imaging twin study.  
University of Copenhagen, Faculty of Health Sciences.  
Defended July 11, 2018.

**Low AM**, CNSR&CINS: Attention, Executive Functioning and Delay Aversion in Adults with newly diagnosed ADHD; Before and after stimulant medication.  
University of Copenhagen, Faculty of Social Science  
Defended on August 17, 2018.

**Jessen K**, CNSR, CINS: Cortical structure in antipsychotic-naïve schizophrenia patients before and after six weeks treatment with a dopamine D<sub>2/3</sub> receptor antagonist: Relation to psychopathology, functions and cognition.  
University of Copenhagen, Faculty of Health Sciences  
Defended on September 11, 2018.

**Axelsen M**, DTU & CNSR, CINS: A multimodal modeling approach to schizophrenia.  
University of Copenhagen, DTU Compute.  
Defended March 26, 2019.

**Jensen MB**, CNSR, CINS: The relationship between cognition and white matter microstructure in initially antipsychotic-naïve schizophrenia patients.  
University of Copenhagen, Faculty of Social Science  
Defended on July 5, 2019.

**Sommer JL**, CNSR, CINS: Effect of treatment with Methylphenidate on early information processing: A longitudinal project on initially psychostimulant-naïve adult ADHD patients.  
University of Copenhagen, Faculty of Health Sciences  
Defended on September 12, 2019.

**Uldall SW**, CNSR, CINS & PC Ballerup: Functional and Structural Neuroimaging in Trauma-Affected Refugees with Posttraumatic Stress Disorder.  
University of Copenhagen, Faculty of Health Sciences  
Defended on September 30, 2019.

**Kristensen TD**, Research Unit, Mental Health Center Copenhagen & CINS: Cerebral white matter and cognition in individuals at ultra-high risk for developing psychosis.  
University of Copenhagen, Faculty of Health and Medical Sciences.  
Defended December 5, 2019.

**Wenneberg C** Research Unit, Mental Health Center Copenhagen & CINS: Glutamatergic and GABAergic disturbances in individuals at ultra-high risk of psychosis: implications for clinical and functional outcome.  
University of Copenhagen, Faculty of Health Sciences.  
Defended February 21, 2020.

**Tangmose K** CINS & CNSR: Reward processing in first-episode psychosis patients and their association to glutamate and dopamine synthesis capacity.  
University of Copenhagen, Faculty of Health Sciences.  
Defended November 23, 2020.

**Randers L** Research Unit, Mental Health Center Copenhagen & CINS: Cognitive Functioning in Subjects at Ultra-High Risk for Psychosis: A Cross-Sectional Case-Control Study.  
University of Copenhagen, Faculty of Health Sciences.  
Defended March 8, 2021.

**Lemvig CK** CINS & CNSR: Delineating Heritable and Environmental Risk Factors in Schizophrenia Spectrum Disorders: A Nation-Wide Twin Study.  
University of Copenhagen, Faculty of Social Sciences, Department of Psychology.  
Defended March 22, 2021.

**Klærke, L** CINS: "Long-term outcome in schizophrenia: A 4 to 18 year follow-up study of symptomatology, recovery and executive functioning in relation to brain structure in initially antipsychotic-naïve first-episode patients".  
University of Copenhagen, Faculty of Social Sciences, Department of Psychology.  
Defended on September 27, 2021.

**Sigvard A** CINS: “Dopamine synthesis and glutamate and GABA levels in antipsychotic-naïve patients with first-episode psychosis and healthy individuals: Association with psychopathology and treatment response or diagnosis”.

University of Copenhagen, Faculty of Social Sciences, Department of Psychology.

Defended on April 22, 2022.

## DOCTORAL DISSERTATIONS

---

### NUMBER OF DOCTORAL DISSERTATIONS

CINS II: 2

**Glenthøj LB**, Research Unit, Mental Health Center Copenhagen & CINS: Optimizing the prediction and treatment of functional impairments in individuals at ultra-high risk for psychosis.

University of Copenhagen, Faculty of Health and Medical Sciences.

Defended on November 5, 2021.

**Baandrup L**, CNSR, CINS: Benzodiazepines and antipsychotics in severe mental illness. Optimizing and characterizing prescribing practice.

University of Copenhagen, Faculty of Health and Medical Sciences.

Defended on June 28, 2019.

## PUBLICATIONS IN PEER-REVIEWED SCIENTIFIC JOURNALS (2009 – APRIL 2022)

---

### CINS I

Number of publications in 2009: 7

Number of publications in 2010: 15

Number of publications in 2011: 18

Number of publications in 2012: 9

Number of publications in 2013: 19

### CINS II

Number of publications in 2014: 20

Number of publications in 2015: 26

Number of publications in 2016: 27

Number of publications in 2017: 29

Number of publications in 2018: 34


Number of publications in 2019: 39

Number of publications in 2020: 47

Number of publications in 2021: 48

Number of publications in 2022: 27

Number of publications 2009 – April 2022: 365



## CINS I

Aggernæs B, Glenthøj BY, Ebdrup BH, Rasmussen H, Lublin H, Oranje B. Sensorimotor Gating and Habituation in Antipsychotic-Naïve, First-Episode Schizophrenia Patients Before and After Six Months Treatment with Quetiapine. *Int J Neuropsychopharm* 2010;13:1383–95.

Albert N, Bertelsen M, Thorup A, Petersen L, Jeppesen P, Le Quach P, Krarup G, Jørgensen P, Nordentoft M. Predictors of recovery from psychosis. Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after five years. *Schizophr Res* 2011;125:257-66.

Andersen R, Fagerlund B, Rasmussen H, Ebdrup BH, Aggernæs B, Gade A, Oranje B, Glenthøj B. The influence of impaired processing speed on cognition in first-episode antipsychotic-naïve schizophrenic patients. *Eur Psychiatr* 2013 Aug;28(6):332-9.

Andersen R, Fagerlund B, Rasmussen H, Ebdrup BH, Aggernæs B, Gade A, Oranje B, Glenthøj B. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. *Psychiatr Res* 2011;187:49-54.

Baandrup L, Jennum P, Lublin H, Glenthøj BY. Treatment options for residual insomnia in schizophrenia. *Acta Psych Scand* 2013;127(1):81-2.

Baandrup L, Voldsgaard I, Cerqueira C, Jølvig LR, Nordentoft M. Den Nationale Skizofrenidatabase. *Ugeskr Laeger* 2012; 174(42):2548.

Baandrup L, Sørensen J, Lublin H, Nordentoft M, Glenthøj B. Association of antipsychotic polypharmacy with health service cost – a register-based cost analysis. *Eur J Health Econ* 2012 Jun;13(3):355-63.

Baandrup L. How Dosing Might Influence the Conclusion in an Antipsychotic Polypharmacy Effectiveness Trial. *Am J Psych (Letters to the Editor)* 2011;168(10):1117.

Baandrup L, Fagerlund B, Jennum P, Lublin H, Hansen JL, Winkel P, Gluud C, Oranje B, Glenthøj B. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial – the SMART trial protocol. *BMC Psychiatr* 2011;11(1):160.

Baandrup L, Allerup P, Lublin H, Nordentoft M, Peacock L, Glenthøj B. Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia outpatients. *Acta Psychiatr Scand* 2010;367-74.

Baandrup L, Gasse C, Jensen VD, Glenthøj B, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia: A Population-Based Nested Case-Control Study. *J Clin Psych* 2010; 71:103-8.

Baandrup L, Allerup P, Nordentoft M, Lublin H, Glenthøj B. Exploring regional variation in antipsychotic co-prescribing practice: A national questionnaire survey. *J Clin Psych* 2010;71:1457-64.

Baandrup L. Patients at a psychiatric residential institution in Djursland. *Ugeskr Laeger* 2010 1;172(9):732; author reply 732.

Baandrup L. Patients at a psychiatric residential institution in Djursland. *Ugeskr Laeger* 2010 1;172(5):351-5.

Bak N, Glenthøj BY, Rostrup E, Larsson H, Oranje B. Source localization of sensory gating: a combined EEG and fMRI study in healthy volunteers. *Neuroimage* 2011;54:2711-8.

Broberg BV, Madsen KH, Plath N, Olsen CH, Glenthøj BY, Paulson OB, Bjelke B, Søgaard LV. A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by Magnetic Resonance Imaging. *Behav Brain Res* 2013;Aug. 250:1-8.

Broberg BV, Oranje B, Glenthøj BY, Fejgin K, Plath N, Bastlund JF. Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia - Gating of auditory-evoked potentials and prepulse inhibition. *Behav Brain Res* 2010;213(2):142-7.

Broberg BV, Glenthøj BY, Dias R, Larsen DB, Olsen CK. Reversal of cognitive deficits by an ampakine (CX516) and Sertindole in two animal models of schizophrenia – sub-chronic and early postnatal PCP treatment in attentional set-shifting. *Psychopharm* 2009;206:631-40.

de Jong S, Boks MP, Fuller TF, Strengman E, Janson E, de Kovel CG, Ori AP, Vi N, Mulder F, Blom JD, Glenthøj B, Schubart CD, Cahn W, Kahn RS, Horvath S, Ophoff RA. A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. *PLoS One*. 2012;7(6):e39498.

De leeuw A, Oranje B, Westenberg HG. Prepulse inhibition and P50 suppression in medication-free patients with obsessive-compulsive disorder. *Int Clin Psychopharm* 2010;25(4):232-40.

Ebdrup BH, Nørbak H, Borgwardt S, Glenthøj BY. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. *Curr Med Chem* 2013;20:438-47.

Ebdrup BH, Knop FK, Ishoy PL, Rostrup E, Fagerlund B, Lublin H, Glenthøj B. Glucagon-like peptide-1 analogues against antipsychotic-induced weight gain: potential physiological benefits. *BMC Medicine* 2012,10(1):92 doi:10.1186/1741-7015-10-92.

Ebdrup BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, Lublin H, Baaré W, Glenthøj B. Progressive striatal and hippocampal volume loss in initially antipsychotic-naïve, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. *Int J Neuropsychopharm* 2011;14:69-82.



Ebdrup BH, Lublin H, Akeson P, Glenthøj B. Patients with first-episode psychosis should not be scanned routinely (article in Danish). *Ugeskr Laeger* 2011 Feb 14;173(7):484-9.

Ebdrup BH, Rasmussen H, Arnt J, Glenthøj BY. Serotonin 2A receptor antagonists for treatment of schizophrenia. Review. *Expert Opin Investig Drugs* 2011;20(9):1211-23.

Ebdrup BH, Glenthøj BY, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB, Lublin H, Skimminge A, Baaré W. Hippocampal and Caudate Volume Reductions in Antipsychotic-Naïve First Episode. *J Psychiatr Neurosci* 2010;35(2):95-104.

Fagerlund B, Pinborg LH, Mortensen EL, Priberg L, Baaré WPC, Gade A, Svarer C, Glenthøj BY. Relationship of frontal D2/3 binding potentials to cognition: a study of antipsychotic-naïve schizophrenia patients. *Int J Neuropsychopharm* 2013 Feb;16(1):23-36.

Hammer TB, Oranje B, Skimminge A, Aggernæs B, Ebdrup BH, Glenthøj B, Baaré W. Structural brain correlates of sensorimotor gating in antipsychotic-naïve men with first-episode schizophrenia. *J Psychiatr Neurosci* 2013 Jan;38(1):34-42.

Hammer TB, Oranje B, Fagerlund B, Bro H, Glenthøj BY. Stability of Prepulse Inhibition and habituation of the Startle Reflex in Schizophrenia: A 6 Year Follow-up Study of Initially Antipsychotic Naïve, First-Episode Schizophrenia patients. *Int J Neuropsychopharm* 2011;14(7):913-25.

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatr* 2013 Feb;14(1):2-44.

Hasan A, Falkai F, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSUMB) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatr* 2012;13(5):318-78.

Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Möller H-J, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietiläinen OPH, Peltonen L, Dempster E, Collier DA, St Clair D, Rasmussen HB, Glenthøj BY, Kiemenev LA, Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ, GROUP Investigators, Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petursson H, Stefansson H, Rujescu D, Stefansson K, Werge T. Maternally derived microduplications at 15q11-q13 implicate imprinted genes in psychotic illness. *Am J Psychiatr* 2011;168(4):408-17.

Ishøy PL, Knop FK, Vilsbøll T, Glenthøj BY, Ebdrup BH. Sustained Weight Loss after Treatment with a GLP-1 Receptor Agonist in an Obese Patient with Schizophrenia and Type 2 Diabetes. Letter to the Editor. *Am J Psychiatr* 2013;170:681-2.

Jepsen JR, Fagerlund B, Pagsberg AK, Christensen AM, Nordentoft M, Mortensen EL. Profile of cognitive deficits and associations with depressive symptoms and intelligence in chronic early-onset schizophrenia patients. *Scand J Psychol* 2013 Oct;54(5):363-70.

Jepsen JR, Fagerlund B, Pagsberg AK, Christensen AM, Hilker RW, Nordentoft M, Mortensen EL. Course of intelligence deficits in early onset, first episode schizophrenia: a controlled, 5-year longitudinal study. *Eur Child Adolesc Psychiatr* 2010;19(4):341-51.

Jepsen JRM, Fagerlund B, Pagsberg K, Christensen AM, Nordentoft M, Mortensen EL. Deficient Maturation of Aspects of Attention and Executive Functions in Early Onset Schizophrenia. *Eur Child Adolesc Psychiatr* 2010;19:773–86.

Jepsen JRM, Fagerlund B, Mortensen EL. Do Attention Deficits Influence IQ Assessment in Children and Adolescents with ADHD? *J Attention Disord* 2009;12:551-62.

Kaalund SS, Riise J, Broberg BV, Fabricius K, Karlsen AS, Secher T, Plath N, Pakkenberg B. Differential Expression of parvalbumin in neonatal phencyclidine-treated rats and socially isolated rats. *J Neurochem*. 2013 Feb;124(4):548-57.

Lau CL, O’Shea RD, Broberg BV, Bischof L, Beart PM. The Rho kinase inhibitor Fasudil up-regulates astrocytic glutamate transport subsequent to actin remodelling in murine cultured astrocytes. *Brit J Pharmacol* 2011;163(3):533-45.

Magnée MJ, Oranje B, van Engeland H, Kahn RS, Kemner C. Cross-sensory gating in schizophrenia and autism spectrum disorder: EEG evidence for impaired brain connectivity? *Neuropsychologia* 2009;47:1728-32.

McGorry PD, Johannesen JO, Lewis S, Birchwood M, Malla A, Nordentoft M, Addington J, Yung A. Early intervention in psychosis: keeping faith with evidence-based health care. *Psychol Med* 2010;40(3):399-404.

McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rossler A, Klosterkotter J, Ruhrmann S, Schiltz-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EY, Keshavan MS, Yung AR. Intervention in individuals at ultra high risk for psychosis: a review and future directions. *J Clin Psych* 2009;70:1206-12.

Nejad AB, Madsen KH, Ebdrup BH, Siebner HR, Rasmussen H, Aggernaes B, Glenthøj B, Baaré WFC. Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naïve schizophrenia patients. *Int J Neuropsychopharmacol* 2013 Jul;16(6):1195-204.

Nejad AB, Ebdrup BH, Fusar-Poli P, Glenthøj BY, Siebner HR. Brain connectivity studies in Schizophrenia: Unravelling the effects of antipsychotics. *Curr Neuropharmacol* 2012 Sep;10(3):219-30.

Nejad AB, Ebdrup BH, Siebner HR, Rasmussen H, Aggernaes B, Glenthøj BY, Baaré WFC. Impaired temporoparietal deactivation with working memory load in antipsychotic naïve patients with first-episode schizophrenia. *World J Biol Psych* 2011;12(4):271-81.

Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenthøj BY. Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients. *Biol Psychiatr* 2012 May 15;71(10):898-905.

Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H, Kapur S, Glenthøj BY. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. *Arch Gen Psychiatr* 2012;69(12):1195-204. 2012 Aug 6:1-10.

Nordholm D, Krogh J, Mondelli V, Dazzan P, Pariante C, Nordentoft M. Pituitary gland volume in patients with schizophrenia, subjects at ultra-high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis. *Psychoneuroendocrinology* 2013 Nov;38(11):2394-404. Review.

Nordentoft M, Glenthøj B, Kessing LV, Parnas J, Werge T, Bech P, Fink-Jensen A, Plessen K, Simonsen E, Nielsen B, Bilberg N, Videbech P, Rosenberg R, Mors O, Mortensen PB, Munk-Jørgensen P, Hove Thomsen P, Licht R, Seinhäuser C. Psychiatric research ought to be central to long-term plans for psychiatry. *Ugeskr Laeger* 2013 Sep 2;175(36):2056-7.

Oranje B, Lahuis B, van Engeland, H, van der Gaag, RJ, Kemner C. Sensory and sensorimotor gating in children with multiple complex developmental disorders (MCDD) and autism. *Psychiatr Res* 2013 Apr 30;206(2-3):287-92.

Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthøj BY. P50 Suppression and its Neural Generators in Antipsychotic-Naive First-Episode Schizophrenia Before and After 6 Months of Quetiapine Treatment. *Schizophr Bull* 2013 Mar;39(2):472-80.

Oranje B, Wienberg M, Glenthøj BY. A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers. *Psych Res* 2011;186:431-6.

Oranje B, Gispen-de Wied CC, Westenberg HGM, Kemner C, Verbaten MN, Kahn RS. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P3000 amplitude. *Int J Neuropsychopharm* 2009;12:823-32.

Pompili M, Serafini G, Innamorati M, Lester D, Shrivastava A, Girardi P, Nordentoft M. Suicide risk in first episode psychosis: A selective review of the current literature. *Schizophr Res* 2011;129(1):1-11.

Rasmussen H, Ebdrup BH, Aggernaes, Lublin H, Oranje B, Pinborg LH, Knudsen GM, Glenthøj BY. Norquetiapine and Depressive Symptoms in Initially Antipsychotic-Naïve First Episode Schizophrenia. *J Clin Psychopharmacol* 2013, vol. 33 (2):266-9.

Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg LH, Baaré WFC, Svarer C, Lublin H, Knudsen GM, Glenthøj BY. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. *Psychopharmacol* 2011;213:583-92.

Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg L, Baaré W, Svarer C, Lublin H, Knudsen GM, Glenthøj B. Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naïve First-episode Schizophrenia Patients. *Arch Gen Psychiatry* 2010;67(1):9-16.

Ripke S et al. Schizophrenia Psychiatric Genome-Wide Association Study identifies five new schizophrenia loci. *Nat Genet* 2011;43(10):969-76.

Schork AJ et al. All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. *PLoS Genet* 2013 Apr;9(4):e1003449.

Secher T, Berezin V, Bock E, Glenthøj B. Effect of an NCAM mimetic peptide FGL on impairment in spatial learning and memory after neonatal phencyclidine treatment in rats. *Behav Brain Res* 2009;199(2):288-97.

Steinberg S et al. Expanding the range of ZNF804A variants conferring risk of psychosis. *Mol Psychiatry* 2011; 16(1):59-66.

Steinberg S et al. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. *Hum Mol Gen* 2011;20:4076-81.

Stober G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, Glenthøj BY, Grunblatt E, Jablensky A, Kim YK, Kornhuber J, McNeil TF, Muller N, Oranje B, Saito T, Saoud M, Schmitt A, Schwartz M, Thome J, Uzbekov M, Durany N, Riederer P. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. *World J Biol Psychiatr* 2009; 10:127-55.

van Lutterveld R, Oranje B, Kemner C, Abramovic L, Willems AE, Boks MP, Glenthøj BY, Kahn RS, Sommer IE. Increased psychophysiological parameters of attention in non-psychotic individuals with auditory verbal hallucinations. *Schizophr Res* 2010;121(1-3):153-9.

van Scheltinga AF, Bakker SC, van Haren NE, Derks EM, Buizer-Voskamp JE, Boos HB, Cahn W, Hulshoff Pol HE, Ripke S, Ophoff RA, Kahn RS; Psychiatric Genome-wide Association Study Consortium Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. *Biol Psychiatr* 2013 Mar 15;73(6):525-31.

van Scheltinga AF, Bakker SC, van Haren NE, Derks EM, Buizer-Voskamp JE, Cahn W, Ripke S; Psychiatric Genome-Wide Association Study (GWAS) Consortium, Ophoff RA, Kahn RS. Schizophrenia genetic variants are not associated with intelligence. *Psychol Med* 2013 Dec;43(12):2563-70.

Ucar E, Lethinen EK, Glenthøj BY, Oranje B. The effects of acute exogenous melatonin on P50 suppression of healthy male volunteers stratified for low and high gating levels. *J Psychopharmacol* 2012 Aug;26(8):1113-8.

Wienberg M, Glenthøj BY, Jensen KS, Oranje B. A Single High Dose of Escitalopram Increases Mismatch Negativity without Affecting Processing Negativity or P300 Amplitude in Healthy Volunteers. *J Psychopharmacol* 2010;24(8):1183-92.

---

## CINS II

Albert N, Melau M, Jensen H, Emborg C, Jepsen JR, Fagerlund B, Gluud C, Mors O, Hjorthøj C, Nordentoft M. Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomized, superiority parallel group trial in Denmark (OPUS II). *BMJ* 2017, Jan 12;356. doi: 10.1136/bmj.i6681

Albert N, Glenthøj LB, Melau M, Jensen H, Hjorthøj C, Nordentoft M. Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5 year follow-up of the OPUS II study. *Schizophr Res* 2017;182:24-30.

Ambrosen KS, Skjerbæk MW, Foldager J, Axelsen MC, Bak N, Arvastson L, Christensen SR, Johansen LB, Raghava JM, Oranje B, Rostrup E, Nielsen MØ, Osler M, Fagerlund B, Pantelis C, Kinon BJ, Glenthøj BY, Hansen LK, Ebdrup BH. A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data. *Transl Psychiatry* 2020 Aug 10;10(1):276. Doi:10.1038/s41398-020-00962-8.

Amin FM, Icco RD, Al-Karagholi MA, Raghava J, Wolfram F, Larsson HBW, Ashina M. Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study. *J Headache Pain* 2021 Aug 21;22(1):98.

Andersen HG, Raghava JM, Svarer C, Wulff S, Johansen LB, Antonsen PK, Nielsen MØ, Rostrup E, Vernon AC, Jensen LT, Pinborg LH, Glenthøj BY, Ebdrup BH. Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients. *Front Neurosci* 2020 May 20;14:484.

Andersen NK, Rimvall MK, Jeppesen P, Bentz M, Jepsen JRM, Clemmensen L, Jacobsen RK, Olsen EM. A psychometric investigation of the multiple-choice version of Animated Triangles Task to measure Theory of Mind in adolescence. *PLoS One* 2022 Mar 10;17(3):e0264319. eCollection.

Andersen-Ranberg N, Poulsen LM, Perner A, Wetterslev J, Mathiesen O, Mortensen CB, Estrup S, Ebdrup BH, Hästbacka J, Citerio G, Caballero J, Morgan MPG, Oxenbøll-Collet M, Weber SO, Andreasen SA, Bestle MH, Pedersen HBS, Nielsen LB, Uslu B, Jensen TB, Thee C, Dey N, Lange T. The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan. *Acta Anaesthesiol Scand* 2020 Oct;64(9):1357-64.

Andersen-Ranberg NC, Poulsen LM, Perner A, Wetterslev J, Estrup S, Lange T, Ebdrup BH, Hästbacka J, Morgan MPG, Citerio G, Zafrani L, Caballero J, Oxenbøll-Collet M, Weber SO, Andreasen AS, Bestle M, Pedersen HBS, Hildebrandt T, Thee C, Jensen TB, Dey N, Nilsen LG, Mathiesen O. The Agents intervening against delirium in the intensive care unit (AID-ICU) – Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU. *Acta Anaesthesiol Scand* 2019 Nov;63(10):1426-33.

Andreassen OA, Harbo HF, Wang Y, Thompson WK, Schork AJ, Mattingsdal M, Zuber V, Bettella F, Ripke S, Kelsoe JR, Kendler KS, O'Donovan MC, Sklar P; The Psychiatric Genomics Consortium (PGC) Bipolar Disorder and Schizophrenia Work Groups; The International Multiple Sclerosis Genetics Consortium (IMSGC), McEvoy LK, Desikan RS, Lie BA, Djurovic S, Dale AM. Genetic Pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: Differential involvement of Immune-Related Gene Loci. *Mol Psych* 2015;20:207-14.

Anhøj S, Nielsen MØ, Jensen MB, Ford K, Fagerlund B, Williamson P, Glenthøj B, Rostrup E. Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia. *Schizophr Bull* 2018 Oct 17;44(6):1332-40.

Axelsen MC, Jepsen JRM, Bak N. The Choice of Prior in Bayesian Modeling of the Information Sampling Task. *Biol Psychiatr* 2018 Jun 15;83(12):e59-e60. 3.] Letter to Editor.

Baandrup L et al. Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models. *Acta Psychiatr Scand* 2022 Apr 13. Online ahead of print.

Baandrup L. Managing the hazards of cannabis use. *Acta Psychiatr Scand* 2022 Mar;145(3):231-3.

Baandrup L, Ebdrup BH. Pragmatic antipsychotics trial-caution in interpretation. *Lancet Psychiatr* 2021 Feb;8(2):100-01.

Baandrup L, Jennum PJ. Effect of a dynamic lighting intervention on circadian rest-activity disturbances in cognitively impaired, older adults living in a nursing home: A proof-of-concept study. *Neurobiol Sleep Circadian Rhythms* 2021 May 24;100067. eCollection 2021 Nov.

Baandrup L, Rasmussen JØ, Mainz J, Videbech P, Kristensen S. Patient-Reported Outcome Measures in Mental Health Clinical Research: A Descriptive Review in Comparison with Clinician-Rated Outcome Measures. *Int J Qual Health Care* 2021 Jan 6. Doi: 10.1093/intghc/mzab001. Online ahead of print.

Baandrup L, Allerup P, Nielsen MØ, Bak N, Düring SW, Leucht S, Galderisi S, Mucci A, Bucci P, Arango C, Díaz-Caneja CM, Dazzan P, McGuire P, Demjaha A, Ebdrup BH, Kahn RS, Glenthøj BY. Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia – data from the OPTiMiSE trial. *Psychiatr Res* 2020 Jul;289:112970.

Baandrup L. Polypharmacy in schizophrenia. *Basic Clin Pharmacol Toxicol* 2020 Mar;126(3):183-92.

Baandrup L, Christensen JAE, Fagerlund B, Jennum P. Investigation of sleep spindle activity and morphology as predictors of neurocognitive functioning in medicated patients with schizophrenia. *J Sleep Res* 2019 Feb;28(1):e12672.

Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users (Review). *Cochrane Library*. *Cochrane Database Syst Rev* 2018 Mar 15;3:CD011481. doi: 10.1002/14651858.CD011481.pub2. Review

Baandrup L, Fagerlund B, Glenthøj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo add on. *Eur Arc Psychiatr Clin Neurosci* 2017 Mar;267(2):163-71.

Baandrup L, Fasmer OB, Glenthøj B, Jennum P. Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial. *BMC Psychiatry* 2016;16(1) s.348.

Baandrup L, Cerqueira C, Haller LG, Korshøj L, Voldsgaard I, Nordentoft M. The Danish Schizophrenia Registry. *Clin Epidemiol* 2016;8:691-5.

Baandrup L, Glenthøj B, Jennum PJ. Objective and subjective sleep quality: melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. *Psychiatr Res* 2016 Apr 15;240:163-9.

Baandrup L, Kruse M. Incident users of antipsychotics: who are they and how do they fare? *Soc Psychiatry Psychiatr Epidemiol* 2016 Apr;51(4):505-12.

Baandrup L, Kruse M. New users of antipsychotic medication: A population-based cohort study of occupational outcome measures in relation to antipsychotic on-label and off-label prescribing practices. *Eur Psychiatr* 2016 Jan;31:66-71.

Baandrup L, Rasmussen JØ, Klokke L, Austin SF, Bjørnshave T, Bliksted VF, Fink-Jensen A, Fohlmann AH, Hansen JP, Nielsen MK, Sandsted KE, Schultz V, Voss-Knude S, Nordentoft M. Treatment of adult patients with schizophrenia and complex mental health needs – A national clinical guideline. *Nord J Psychiatr* 2016 Apr;70(3):231-40.

Baandrup L, Lindschou J, Winkel P, Gluud C, Glenthøj BY. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial. *World J Biol Psychiatr* 2016;17(7):514-24.

Baandrup L, Jennum A. A validation of wrist actigraphy against polysomnography in patients with schizophrenia or bipolar disorder. *Neuropsychiatric disease and treatment* 2015 Aug 28;11:1171-7.

Baandrup L, Ebdrup BH, Lindschou J, Gluud C, Glenthøj BY. Pharmacological Interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Protocol for Cochrane Review, 2015 jan.s.CDO11481.

Bak N, Mann J, Fagerlund F, Glenthøj BY, Jepsen JRM, Oranje B. Testing a decades' old assumption: are individuals with lower sensory gating indeed more easily distracted. *Psychiatr Res* 2017 May 31;255:387-93.

Bak N, Ebdrup BH, Oranje B, Fagerlund B, Jensen MH, Düring SW, Nielsen MØ, Glenthøj BY, Hansen LK. Two subgroups of antipsychotic-naïve, first-episode schizophrenia patients identified with a Gaussian Mixture Model on cognition and electrophysiology. *Transl Psychiatr* 2017 Apr 11;7(4):e1087. doi: 10.1038/tp.2017.59 (online publ).

Bak N, Hansen LK. Data driven estimation of imputation error - A strategy for imputation with a reject option. *PLOS ONE* 2016;1(10):e0164464. doi: 10.1371/journal.pone.0164464. eCollection 2016.

Bak N, Rostrup E, Larsson H, Glenthøj B, Oranje B. Concurrent fMRI and EEG assessment of Sensory Gating in Schizophrenia. *Hum Brain Mapp* 2014 Aug;35(8):3578-87.

Baltzersen OB, Meltzer HY, Frokjaer VG, Raghava JM, Baandrup L, Fagerlund B, Larsson HBW, Fibiger HC, Glenthøj BY, Knudsen GM, Ebdrup BH. Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders with Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. *Front Pharmacol* 2020 Apr 30;11:591. eCollection

Barbosa S, Martinuzzi E, Sommer IE, Dazzan P, McGuire P, Arango C, Diaz-Caneja CM, Fleischhacker WW, Rujescu D, Glenthøj B, Rossum IWv, Kahn RS, Yolken R, Lewis S, Drake R, Leucht S, Gilet C, Khalfallah O, Davidovic L, Ibrahim EC, Belzeaux R, Leboyer M, Glaichenhaus N and the OPTiMiSE Study Group. Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. *Schizophr Bull Open* 2021 May 27;2(1).

Bentz M, Westwood H, Jepsen JRM, Plessen KH, Tchanturia K. The autism diagnostic observation schedule: Patterins in individuals with anorexia nervosa. *Eur Eat Disord* 2020 Sep;28(5):571-9.

Bentz M, Jepsen JR, Kjaersdam Tellés G, Moslet U, Pedersen T, Bulik CM, Plessen KJ. Neurocognitive functions and social functioning in young females with recent-onset anorexia nervosa and recovered individuals. *Int J Eat Disord*. 2017 Feb 27;5:5-10. doi: 10.1186/s40337-017-0137-3. eCollection 2017 Feb 27.

Bentz M, Guldborg J, Vangkilde S, Pedersen T, Plessen KJ, Jepsen JR. Heightened Olfactory Sensitivity in Young Females with Recent-Onset Anorexia Nervosa and Recovered Individuals. *PLoS One* 2017 Jan 6;12(1):e0169183. doi: 10.1371/journal.pone.0169183. eCollection 2017 Jan 6.

Bentz M, Jepsen JRM, Pedersen T, Bulik CM, Pedersen L, Pagsberg Ak, Plessen KJ. Impairment of social function in young females with recent onset anorexia nervosa and recovered individuals. *J Adolesc Health* 2017 Jan;60(1):23-32.

Berendsen S, EU-GEI High Risk Study (Glenthøj BY, Nordholm D, Randers L, Krakauer K, Glenthøj LB). Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. *Schizophr Res* 2021 Apr;230:104-7.

Bergh S, Hjorthøj C, Sørensen HJ, Fagerlund B, Austin S, Secher RG, Jepsen JR, Nordentoft M. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study. *Schizophr Res* 2016 aug;175(1-3):57-63.

Bertelsen B, Oranje B, Melchior L, Fagerlund B, Werge TM, Mikkelsen JD, Tümer Z, Glenthøj BY. Association study of CHRNA7 promoter variants with sensory- and sensorimotor gating in schizophrenia patients and healthy controls – A Danish case-control study. *NeuroMolecul Med* 2015 Dec;17(4):423-40.

Bertelsen B, Melchior L, Tümer Z, Groth C, Mol Debes N, Skov L, Holst KK, Fagerlund B, Mikkelsen JD. Association of the CHRNA7 promoter variant - 86T with Tourette syndrome and comorbid OCD. *Psychiatry Res* 2014 Nov 30;219(3):710-1.

Bertelsen B, Melchior L, Jensen LR, Groth C, Glenthøj B, Rizzo R, Debes NM, Skov L, Brøndum-Nielsen K, Paschou P, Silahatoglu A, Tümer Z. Intragenic deletions affecting two alternative transcripts of the *IMMP2L* gene in patients with Tourette syndrome. *Eur J Hum Genet* 2014 Nov;22(11):1283-9.

Bliksted V, Frith C, Videbech P, Fagerlund B, Emborg C, Simonsen A, Roepstorff A, Campbell-Meiklejohn D. Hyper- and hypo-mentalizing in patients with first-episode schizophrenia: fMRI and behavioural studies. *Schizophrenia Bulletin* 2019 Mar 7;45(2):377-85.

Bliksted V, Videbech P, Fagerlund B, Frith C. The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms. *Neuropsychology* 2017 Feb;31(2):209-19.

Bliksted V, Fagerlund B, Weed E, Frith C, Videbech P. Social cognition and neurocognitive deficits in first-episode schizophrenia. *Schizophr Res* 2014;153:9-17.

Bojesen KB, Broberg BV, Fagerlund B, Jessen K, Thomas MB, Sigvard A, Tangmose K, Nielsen MØ, Andersen GS, Larsson HBW, Edden RAE, Rostrup E, Glenthøj BY. Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients with Schizophrenia or Psychosis. *Biol Psychiatr* 2021 Feb 1;89(3):278-87.

Bojesen KB, Ebdrup BH, Jessen K, Sigvard A, Tangmose K, Edden RAE, Larsson HBW, Rostrup E, Broberg BV, Glenthøj BY. Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis. *Psychol Med* 2020 Oct;50(13):2182-93.

Bojesen KB, Andersen KA, Rasmussen SN, Baandrup L, Madsen LM, Glenthøj BY, Rostrup E, Broberg BV. Glutamate levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately following Infusion of S-Ketamine in Healthy Volunteers. *Front Psych* 2018, Feb 6;9:22. Doi:10.3389/fpsy.2018.00022. eCollection 2018.

Broberg BV, Sommer IE, Benros ME, Glenthøj B, Gasse C, Köhler-Forsberg O. Glucocorticoids and the risk of psychosis in childhood and adolescence – a Danish nationwide study. *Schizophr Res* 2018 Sep;199:116-22.

Bucci P, Mucci A, van Rossum IW, Aiello C, Arango C, Baandrup L, Buchanan RW, Dazzan P, Demjaha A, Díaz-Caneja Cm, Giordano GM, Glenthøj BY, Leucht S, McGuire P, Rodriguez-Jimenez R, Vignapialo A, Kahn RS,



Galerisi S. Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. *Eur Neuropsychopharmacol* 2020 May;34:76-86.

Burton BK, Andersen KK, Greve AN, Hemager N, Spang KS, Ellersgaard D, Christiani CJ, Gantriis D, Gregersen M, Søndergaard A, Jepsen JRM, Bliksted VF, Mors O, Plessen KJ, Nordentoft M, Thorup AAE. Sex differences across developmental domains among children with familial risk of severe mental disorders. *Psychol Med* 2022 Feb 14:1-16. Online ahead of print.

Burton BK, Petersen A, Eichele H, Hemager N, Spang KS, Ellersgaard D, Christiani CJ, Greve A, Gantriis D, Jepsen JRM, Mors O, Nordentoft M, Thorup AA, Plessen KJ, Vangkilde S. Post-error adjustment among children aged 7 years with a familial high risk of schizophrenia or bipolar cohort study. *Dev Psychopathol* 2021 May 17;1-11. Online ahead of print

Burton BK, Vangkilde S, Petersen A, Skovgaard LT, Jepsen JR, Hemager N, Christiani CJ, Spang KJ, Ellersgaard D, Greve A, Gantriis D, Eichele H, Mors O, Nordentoft M, Thorup AAE, Plessen KJ. Sustained Attention and Interference Control Among 7-Year-Old Children With familial High Risk of Schizophrenia or Bipolar Disorder- A Observational Cohort Study. *Biol Psychiatr Cogn Neurosci Neuroimaging* 2018 Aug;3(8):704-12.

Burton BK, Thorup AA, Jepsen JR, Poulsen G, Ellersgaard D, Spang KS, Christiani CJ, Hemager N, Gantriis D, Greve A, Mors O, Nordentoft M, Plessen KJ. Impairments of motor function among children with a familial risk of schizophrenia or bipolar disorder at 7 years old in Denmark: an observational cohort study. *Lancet Psychiatry* 2017 May;4(5):400-8.

Burton BK, Hjorthøj C, Jepsen JR, Thorup A, Nordentoft M, Plessen KJ. Research Review: Do motor deficits during development represent an endophenotype for schizophrenia? A meta-analysis. *J Child Psychol Psychiatry* 2016 Apr;57(4):446-56.

Cantion C, White S, Madsen GF, Bilenberg N, Jepsen JRM. Do cognitive deficits persist into adolescence in autism? *Autism Res* 2018 Sep;11(9):1229-38.

Cantio C, Jepsen JRM, Madsen GF, Bilenberg N, White SJ. Exploring 'The Autism' at a Cognitive level. *Autism Res* 2016;9(12):1328-39.

Christensen JAE, Jennum PJ, Fagerlund B, Baandrup L. Association of neurocognitive functioning with sleep stage dissociation and REM sleep instability in medicated patients with schizophrenia. *J Psychiatr Res* 2021 Apr;136:198-203.

Christiani CJ, Hemager N, Ellersgaard D, Thorup AAE, Spang KS, Burton BK, Gregersen M, Søndergaard A, Greve A, Gantriis DL, Mors O, Plessen KJ, Nordentoft M, Jepsen JRM. Heterogeneity of social cognitive and language functions in children at familial high-risk of severe mental illness; The Danish High Risk and Resilience Study VIA 7. *Eur Child Adolesc Psychiatr* 2021 Feb 9. Doi: 10.1007/s00787-021-01722-9. Online ahead of print.

Christiani CJ, Jepsen JRM, Thorup A, Hemager N, Ellersgaard D, Spang KS, Burton BK, Gregersen M, Søndergaard A, Greve An, Gantriis DL, Poulsen G, Uddin MJ, Seidman LJ, Mors O, Plessen KJ, Nordentoft M. Social Cognition, Language, and Social Behavior in 7-Year-Old Children at Familial High-Risk of Developing Schizophrenia or Bipolar Disorder: The Danish High Risk and Resilience Study VIA 7-A Population-Based Cohort Study. *Schizophr Bull* 2019;45(6):1218-30.

Clemmensen L, Bouchard S, Rasmussen J, Holmberg TT, Nielsen NH, Jepsen JRM, Lichtenstein MB. Study Protocol: Exposure in Virtual Reality for Social Anxiety Disorder – a randomised controlled superiority trial comparing cognitive behavioral therapy with virtual reality based exposure to cognitive behavioral therapy with in vivo exposure. *MBC Psychiatr* 2020 Jan 30;20(1):32.

Clemmensen L, Jepsen JRM, van Os J, Blijd-Hoogewys EMA, Rimvall MK, Olsen EM, Rask CU, Bartels-Velthuis AA, Skovgaard AM, Jeppesen P. "Are Theory-of-Mind and bullying separately associated with later academic performance among preadolescents?" 2020 Mar;90(1):62-76.

Clemmensen L, Bartels-Velthuis AA, Jespersen R, van Os J, Blijd-Hoogewys EMA, Ankerstrøm L, Væver M, Daniel DF, Drukker M, Jeppesen P, Jepsen JRM. A Psychometric Evaluation of the Danish Version of the Theory of Mind Storybook for 8-14 Year-Old Children. *Front Psychol* 2016 marts 8;7:artikel 330 s1-10.

Coello K, Broberg BV, Bak N, Knop FK, Madsen A, Mortensen HB, Søgaaard B, Szecsi PB, Lublin H, Ebdrup BH. Postprandial Prolactin suppression appears absent in antipsychotic-treated male patients. *Psychoneuroendocrinol* 2015 Oct;60:1-6.

Collet MO, Egerod I, Thomsen T, Wetterslev J, Lange T, Ebdrup BH, Perner A. Risk factors for long-term cognitive impairment in ICU survivors: A multicenter, prospective cohort study. *Acta Anaesthesiol Scand* 2021;65 (1):92-9.

Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK. The Clozapine to norclozapine ratio: A narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. *Exp Opin Drug Safety* 2020 Jan;19(1):43-57.

Dannevang AL, Randers L, Gondan M, Krakauer K, Nordholm D, Nordentoft M. Premorbid adjustment in individuals at ultra-high risk for developing psychosis: a case-control study. *Early Intervent Psychiatr* 2018;12:839-47.

Dazzan P, Lawrence AJ, Reinders SAATS, Egerton A, van Haren NEM, Merritt K, Barker GJ, Perez-Ingelias R, Sendt KV, Demjaha A, Nam KW, Sommer IE, Pantelis C, Fleischhacker W, van Rossum IW, Galderisi S, Mucci A, Drake R, Lewis S, Weiser M, Diaz-Caneja CMM, Janssen J, Diaz-Marsa M, Rodriguez Arango C, Baandrup L, Broberg B, Rostrup E, Ebdrup BH, Glenthøj B, Kahn RS, McGuire P & OPTiMiSE study Group. Symptom remission and brain cortical networks at first clinical presentation of psychosis: the OPTiMiSE study. *Schizophr Bull* 2021 Mar 16;47(2):444-55.

Dazzan P, Arango C, Fleischhacker W, Galderisi S, Glenthøj B, Leucht S, Meyer-Lindenberg A, Kahn R, Rujescu D, Sommer I, Winter I, McGuire P. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. *Schizophr Bull* 2015;41(3):574-83.

Debes N, Jeppesen S, Raghava JM, Groth C, Rostrup E, Skov L. Longitudinal Magnetic Resonance Imaging (MRI) Analysis of the developmental Changes of Tourette Syndrome Reveal Reduced Diffusion in the Cortico-Striato-Thalamo-Cortical Pathways. *J Child Neurol* 2015(30):10:315-26.

Demjaha A, Galderisi S, Glenthøj B, Arango C, Mucci A, Lawrence A, O'Daly O, Kemptom M, Ciufolini S, Baandrup L, Ebdrup BH, Rodrigues-Jimenez R, Diaz-Marsa M, Díaz-Caneja CM, van Rossum IW, Kahn R, Dazan P, McGuire P. Negative symptoms in First-Episode Schizophrenia related to morphometric

alterations in orbitofrontal and superior temporal cortex: The OPTiMiSe study. *Psychol Med* 2022 Feb 24;1-9. Online ahead of print.

Desler C, Frederiksen JH, Angleys M, Maynard S, Keijzers G, Fagerlund B, Mortensen EL, Osler M, Lauritzen M, Bohr VA, Rasmussen LJ. Increased deoxythymidine triphosphate levels is a feature of relative cognitive decline. *Mitochondrion* 2015 Sep 25;25:34-7.

Dickens Am et al. EU-GEI High Risk Study Group. Dysregulated Lipid Metabolism Precedes Onset of Psychosis. *Biol. Psychiatr* 2021 Feb 1;89(3):288-97.

Dollfus S, Mucci A, Giordano GM, Bitter I, Austin SF, Delouche C, Erfurth A, Fleischhacker WW, Movina L, Glenthøj B, Güetter K, Hofer A, Hubenak J, Kaiser S, Libiger J, Melle I, Nielsen MØ, Papsuev O, Rybakowski JK, Sachs G, Úcok A, Brando F, Wojcziak P, Falderisi S. European validation of Self-evaluation of Negative Symptoms (SNS): A large multinational and multicenter study. *Frontiers Psychiatr* 2022 Jan 31;13:826465. eCollection.

Doser K, Andersen EW, Kenborg L, Dalton SO, Jepsen JRM, Krøyer A, Østergaard J, Hoved H, Sørensen SA, Johansen C, Mullvihill J, Winther JF, Bidstrup PE. Clinical characteristics and quality of life, depression, and anxiety in adults with neurofibromatosis type 1: A nationwide study. *Am J Med Genet A* 2020 Jul;182(7):1704-15.

Drake DJ, Nordentoft M, Haddock G, Arango C, Fleischhacker WW, Glenthøj BY, Leboyer M, Leucht S, Leweke M, McGuire P, Meyer-Lindenberg A, Rujescu D, Sommer IE, Kahn RS, Lewis SW. Modeling Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention. *Schizophr Bull* 2015;41(3):584-96.

Düring S, Nielsen MØ, Bak N, Glenthøj B, Ebdrup BH. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade – An exploratory study. *Psychiatr Res* 2019;271:58-65.

Düring SW, Glenthøj BY, Oranje B. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients. *Int J Neuropsychopharmacol* 2015;9(3).

Düring S, Glenthøj BY, Andersen GS, Oranje B. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naïve, first-episode schizophrenia patients. *Neuropsychopharm* 2014 Dec;39:3000-8.

Ebdrup BH, Knop FK. Weight gain on antipsychotics – A perfect storm of complex pathophysiology and psychopharmacology. *Acta Psychiatr Scand* 2021 Dec;144(6):521-3.

Ebdrup BH, Axelsen M, Bak N, Fagerlund B, Oranje B, Raghava JM, Nielsen MØ, Rostrp E, Hansen LK, Glenthøj BY. Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients. *Psychol Med* 2019 Dec;49(16):2754-63.

Ebdrup BH, Broberg BV, Ishøy PL, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Knop FK, Glenthøj BY. Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial. *Diabetes Obes Metab* 2018 May;20(5):1327-1328.

Ebdrup BE. Skizofreni er et klinisk og neurobiologisk heterogent syndrom. *UFL* 2018;180:237-40.

Ebdrup BE, Fagerlund BF, Ishøy PL, Broberg BV, Bak N, Knop FK, Glenthøj BY. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia: Authors response. Letter to the Editor. *Acta Psychiatr Scand* 2017 Aug 28;135 (5):526-7.

Ebdrup BH, Raghava JM, Nielsen MØ, Rostrup E, Glenthøj B. Frontal fasciculi and psychotic symptoms in antipsychotic-naïve schizophrenia before and after 6 weeks of selective Dopamine D2/3 receptor blockade. *J Psychiatry Neurosci* 2016;14(2):133-41.

Ebdrup BH, Skovgaard N, Raghava JM, Glenthøj BY. Der er forandringer i hjernens ledningsbaner ved skizofreni. *Ugeskr Laeger* 2014;176:2-6.

Ebdrup BH, Knop FK, Madsen A, Mortensen HB, Sjøgaard B, Holst JJ, Szecsi PB, Lublin H. Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. *J Clin Psychiatr* 2014 Sep;75(9):e899-905. doi: 10.4088/JCP.13m08820.

Egerton A, Marsman A, Broberg BV, Hulshoff Pol HE. Editorial: MR Spectroscopy in Neuropsychiatry. *Front Psychiatr* 2018 May 31;9:197. doi: 10.3389/fpsyt.2018.00197. eCollection 2018.

Egerton A, Broberg B, van Haren N, Merritt K, Barker G, Lythgoe D, Perez-Iglesias R, Baandrup L, Rostrup E, Durrant J, Sendt KV, Stone J, Sommer I, Glenthøj B, Dazzan P, McGuire P. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: A multicentre 1H-MRS study (OPTiMiSE). *Mol Psychiatr* 2018 Nov;23(11):2145-55.

Ellersgaard D, Gregersen M, Ranning A, Haspang TM, Christiani C, Hemager N, Burton BK, Spang KS, Søndergaard A, Greve A, Gantriis D, Jepsen JRM, Mors O, Plessen KJ, Nordentoft M, Thorup AAE. Quality of life and self-esteem in 7-year-old children with familial high risk of schizophrenia or bipolar disorder: the Danish High Risk and Resilience Study-VIA 7 – a population-based cohort study. *Eur Child Adolesc Psychiatr* 2020 Jun;29(6):849-60.

Ellersgaard D, Plessen KJ, Jepsen JR, Spang KS, Hemager N, Burton BK, Christiani CJ, Gregersen M, Søndergaard A, Uddin MJ, Poulsen G, Greve A, Gantriis D, Mors O, Nordentoft M, Thorup AAE. Psychopathology in 7-year-old children with familial high risk of developing schizophrenia spectrum psychosis or bipolar disorder – The Danish Risk and Resilience Study – VIA 7, a population-based cohort study. *World Psychiatr* 2018 Jun;17(2):210-9.

Eriksson R, Broberg BV, Ishøy PL, Bak N, Andersen UB, Jørgensen NR, Knop FK, Ebdrup BH. Bone Status in Obese, Non-Diabetic, Antipsychotic-Treated Patients and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. *Front Psychiatr, section Schizophrenia* 2019 Jan 28;9:781.

Fagerlund B, Pantelis C, Jepsen JRM, Raghava JM, Rostrup E, Thomas MB, Nielsen MØ, Bojesen K, Jensen KG, Stentebjerg-Decara M, Klauber DG, Rudå D, Ebdrup BH, Jessen K, Sigvard A, Tangmose K, Jeppesen P, Correll CU, Fink-Jensen A, Pagsberg AK, Glenthøj BY. Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years. *Psychological Med* 2021, Jul;51(9):1570-80.

- Fond G, d'Albis MA, Jamain S, Tamouza R, Arango C, Fleischhacker WW, Glenthøj B, Leweke M, Lewis S, McGuire P, Meyer-Lindenberg A, Sommer IE, Winter-van Rossum I, Kapur S, Kahn RS, Rujescu D, Leboyer M. The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. *Schizophr Bull* 2015;41(3):559-73.
- Fraguas D, Díaz-Caneja CM, Pina-Camacho L, Winter van Rossum I, Baandrup L, Sommer IE, Glenthøj B, Kahn RS, Leucht S, Arango C. The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study. *Schizophr Res* 2021 May;231:100-7
- Frandsen R, Baandrup L, Kjellberg J, Ibsen R, Jennum P. Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: A natural register-based study. *Parkinsonism and Related disorders* 2014;20(11):124-8.
- Frederiksen LE, Erdmann F, Mader L, Mogensen H, Pedersen C, Kenborg L, Bautz A, Talbäck M, Hirvonen E, Nielsen TT, Andersen EAW, Holmqvist AS, Jørgensen OS, Jepsen JRM, Malila N, Hasle H, Madanat-Harjuoja L, Feychting M, Winther JF. Psychiatric disorders in childhood cancer survivors in Denmark, Finland, and Sweden: a register-based cohort study from the SALiCCS research programme. *Lancet* 2022 Jan;9(1):35-45.
- Fusaroli R, Grossman R, Bilenberg N, Cantio C, Jepsen JRM, Weed E. Toward a cumulative science of vocal markers of autism: A cross-linguistic meta-analysis-based investigation of acoustic markers in American and Danish autistic children. *Autism Res* 2022 Apr;15(4):653-64.
- Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabé M, Giordano GM, Nielsen MØ, Glenthøj LB, Pezzella P, Falkai P, Dollfus S, Gaebel W. EPA guidance on assessment of negative symptoms in schizophrenia. *Eur Psychiatr* 2021 Feb 18;64(1):e23. Free PMC article.
- Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabé M, Giordano GM, Nielsen MØ, Glenthøj LB, Pezzella P, Falkai P, Dollfus S, Gaebel W. EPA guidance on treatment of negative symptoms in schizophrenia. *Eur Psychiatr* 2021 Mar 17;64(1):e21. PMID:33597064 Free PMC article.
- Gantriis DL, Thorup AAE, Harder S, Greve AN, Henriksen MT, Zahle MT, Zahle KK, Stadsgaard H, Ellersgaard D, Burton BK, Christiani CJ, Spang K, Hemager N, Uddin MH, Jepsen JRM, Plessen KJ, Nordentoft M, Mors O, Bliksted V. Home visits in the Danish High Risk and Resilience Study – VIA 7: assessment of the home environment of 508 7-year-old children born to parents diagnosed with schizophrenia or bipolar disorder. *Acta Psychiatr Scand* 2019 Aug;140(2):126-34.
- Gbyl K, Rostrup E, Raghava JM, Andersen C, Rosenberg R, Larsson HBW, Videbech P. Volume of hippocampal subregions and clinical improvement following electroconvulsive therapy in patients with depression. *Prog Neuropsychopharmacol Biol Psychiatr* 2021 Jan 10;104:110048.
- Gbyl K, Rostrup E, Raghava JM, Carlsen JF, Schmidt LS, Lindberg U, Ashraf A, Jørgensen MB, Larsson HBW, Rosenberg R, Videbech P. Cortical thickness following electroconvulsive therapy in patients with depression: a longitudinal MRI study. *Acta Psychiatr Scand* 2019 Sep;140(3):205-16.
- Gehr J, Glenthøj BY, Nielsen MØ. Validation of the Danish Version of the Brief Negative Symptom Scale. *Nord J Psychiatr* 2019 Oct;73(7):425-32.
- Glenthøj B, Fibiger HC. In Memoriam: Arvid Carlsson – Pioneering Researcher and Nobel Laureate. *Neuropsychopharmacology* 2019 Jan;44(2):457-8.

Glenthøj LB, Kristensen TD, Wenneberg C, Hjorthøj C, Nordentoft M. Predictors of remission from the ultra-high risk state for psychosis. *Early Interv Psychiatr* 2021 Feb;15(1)\_104-12.

Glenthøj LB, Mariegaard LS, Fagerlund B, Jepsen JRM, Kristensen TD, Wenneberg C, Krakauer K, Medalia A, Roberts DL, Hjorthøj C, Nordentoft M. Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. *Schizophr Res* 2020 Oct;224:151-8.

Glenthøj LB, Mariegaard LS, Fagerlund B, Jepsen JRM, Kristensen TD, Wenneberg C, Krakauer K, Medalia A, Roberts DL, Hjorthøj C, Nordentoft M. Effectiveness of cognitive remediation in the ultra-high risk state for psychosis. *World Psychiatr* 2020 Oct;19(3):401-2.

Glenthøj LB, Kristensen TD, Wenneberg C, Hjorthøj C, Nordentoft M. Predictors of remission from the ultra-high risk state for psychosis. *Early Interv Psychiatr* 2020 Jan 7. Doi:10.1111/eip.12917 (E-pub ahead of print).

Glenthøj LB, Kristensen TD, Gibson CG, Jepsen JRM, and Nordentoft M. Assessing social skills in individuals at ultra-high risk for psychosis: Validation of the High Risk Social Challenge task (HiSoC). *Schizophr Res* 2020 Jan;215:365-70.

Glenthøj LB, Bailey B, Kristensen TD, Wenneberg C, Hjorthøj C, Nordentoft M. Basic symptoms influence real-life functioning and symptoms in individuals at high risk for psychosis. *Acta Psychiatr Scand* 2019, Oct 16. Doi: 10.1111/acps.13117. (E-pub ahead of print)

Glenthøj LB, Albert N, Fagerlund B, Kristensen TD, Wenneberg C, Hjorthøj C, Nordentoft M, Jepsen JRM. Emotion recognition latency, but not accuracy relates to real life functioning in individuals at ultra-high risk for psychosis. *Schizophr Res Schizophr Res* 2019 Aug;210:197-202.

Glenthøj LB, Fagerlund B, Bak N, Hjorthøj C, Gregersen M, Kristensen TD, Wenneberg C, Krakauer K, Ventura J, Jepsen JRM, Nordentoft M. Examining Speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Association with symptoms and cognition. *Schizophr Res* 2018 May;195:562-3.

Glenthøj LB, Hjorthøj C, Kristensen TD, Davidson CA, Nordentoft M. The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review. *NPJ Schizophr* 2017 May 8;3:20. doi: 10.1038/s41537-017-0021-9. eCollection 2017.

Glenthøj LB, Jepsen JR, Hjorthøj C, Bak N, Kristensen TD, Wenneberg C, Krakauer K, Nordentoft M, Fagerlund B. Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. *Acta Psychiatr Scand* 2017;135(3):250-8.

Glenthøj LB, Fagerlund B, Hjorthøj C, Jepsen JRM, Bak N, Kristensen TD, Wenneberg C, Krakauer K, Roberts DL, Nordentoft M. Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning? *Schizophr Res: Cognition* 2016;5:21-7.

Glenthøj LB, Fagerlund B, Randers L, Hjorthøj CR, Wenneberg C, Krakauer K, Vosgerau A, Glud C, Medalia A, Roberts DL, Nordentoft M. The FOCUS trial: Cognitive remediation therapy plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis. Study protocol of a randomised clinical trial. *Trials* 2015;16(1):25.

Greve AN, Uher R, Als TD, Jepsen JRM, Mortensen EL, Gantriis DL, Ohland J, Burton BK, Ellersgaard D, Christiani CJ, Spang KS, Hemager N, Plessen KJ, Thorup AAE, Bliksted V, Nordentoft M, Mors O. A

Nationwide Cohort Study of Nonrandom Mating in Schizophrenia and Bipolar Disorder. *Schizophr Bull* 2021 Aug;47(5):1342-50.

Hagstrøm J, Spang KS, Vangkilde S, Maigaard K, Skov L, Pagsberg AK, Jepsen JRM, Plessen KJ. An observational study of emotion regulation in children with Tourette syndrome. *J Child Psychol Psychiatr* 2021 Jun;62(2):790-7.

Hagstrøm J, Spang KS, Christiansen BM, Maigaard K, Vanghilde S, Esbjørn BH, Jepsen JRM, Plessen KJ. The Puzzle of Emotion Regulation: Development and Evaluation of the Tangram Emotion Coding Manual for Children. *Front Psychiatr* 2019 Oct 11;10:723. Doi:10.3389/fpsy.2019.00723. eCollection.

Hansen NL, Lauritzen M, Mortensen EL, Osler M, Avlund K, Fagerlund B, Rostrup E. Subclinical Cognitive Decline in Middle-age is Associated with Reduced Task-induced Deactivation of the Brain's Default Mode Network. *Hum Brain Mapp* 2014 Sep;35(9):4488-98.

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. *J Psychiatr Clin Practice* 2017;21(2):82-90.

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia, Part 3. *World J Biol Psychiatr* 2015 Apr;16(3):142-70.

Haß K, Bak N, Szycik G, Glenthøj BY, Oranje B. Deficient prepulse inhibition of the startle reflex in schizophrenia using a cross-modal paradigm. *Biol Psychol* 2017;128:112-6.

Hemager N, Christian CJ, Thorup AAE, Spang KS, Ellersgaard D, Burton BK, Gregersen M, Greve AN, Wang Yunpeng, Nudel R, Mors O, Plessen KJ, Nordentoft M, Jepsen JRM. Neurocognitive heterogeneity in 7-year-old children at familial high risk of schizophrenia or bipolar disorder: The Danish high risk and resilience study – VIA 7. *J Affect Disord* 2022 Apr 1;302:214-23.

Hemager N, Jepsen JRM, Thorup A, Christiani C, Ellersgaard D, Spang KS, Burton BK, Gregersen M, Søndergaard A, Greve AN, Gantriis DL, Mors O, Nordentoft M, Plessen KJ. Decision making and its associations to neurocognitive functions, psychopathology, and the home environment in seven-year-old children at familial high risk of schizophrenia or bipolar disorder: The Danish High Risk and Resilience Study VIA 7. *J Affect Disord* 2021 Feb 15;281:609-17.

Hemager N, Vangkilde S, Thorup A, Christiani C, Ellersgaard D, Spang KS, Burton BK, Greve AN, Gantriis DL, Mors O, Jensen JRM, Nordentoft M, Plessen KJ. Visual attention in 7-year-old children at familial high risk of schizophrenia or bipolar disorder: The Danish high risk and resilience study VIA 7. *J Affect Disord* 2019 Nov 1;258:56-65.

Hemager N, Plessen KJ, Thorup A, Christiani C, Ellersgaard D, Spang KS, Burton BK, Gregersen M, Søndergaard A, Greve AN, Gantriis DL, Poulsen G, Seidman LJ, Mors O, Nordentoft M, Jepsen JRM. Assessment of Neurocognitive Functions in 7-Year-Old Children at Familial High Risk for Schizophrenia or Bipolar Disorder: The Danish High Risk and Resilience Study VIA 7. *JAMA Psychiatr* 2018 Aug 1;75(8):844-52.

Henriksen OM, Gjedde A, Vang K, Law I, Aanerud J, Rostrup E. Regional and interindividual relationships between cerebral perfusion and oxygen metabolism. *J Appl Physiol* 2021 Jun 1 ;130(6) :1836-47.

Hilker R & Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, Nordentoft M, Glenthøj B. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish Twin Registers. *Biol Psychiatr* 2018 ;83(6) :492-8.

Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, Nordentoft M, Glenthøj B. Is an early age at illness onset in schizophrenia associated with increased genetic susceptibility? Analysis of data from the nationwide Danish Twin Register. *EBio Medicine* 2017 Apr;18:320-26. doi: 10.1016/j.ebiom.2017.04.002.

Hoeffding LK, Neilsen MH, Nissen J, Didriksen M, Werge T, Schow T, Erikstrup C, Pedersen OB, Bjalgrim H, Jepsen JRM, Ullum H, Burgdorf K. Symptoms of ADHD are highly common in undiagnosed adults – A cross-sectional study in a large population of Danes. *Psychiatr Behav Sciences* 2018 May 17; Online edition: <http://meddocsonline.org>

Holst LM, Kronborg JB, Jepsen JRM, Christensen JØ, Vejstrup NG, Juul K, Bjerre JV, Bilenberg N, Ravn HB. Attention-Deficit/Hyperactivity-Disorder symptoms in children with surgically corrected Ventricular Septal Defect, Transposition of the Great Arteries and Tetralogy of Fallot. *Cardiol Young* 2020 Feb;30(2):180-7.

Horsdal HT, Wimberley T, Köhler-Forsberg O, Baandrup L, Gass C. Association between global functioning at first schizophrenia diagnosis and treatment resistance. *Early Interv Psychiatr* 2018;12(6):1198-202.

Horwitz A, Mortensen EL, Osler M, Fagerlund B, Lauritzen M, Benedek K. Passive Double-Sensory Evoked Coherence Correlates with Long-Term Memory Capacity. *Frontiers in Human Neurosci* 2017;11:598.

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerero A, Hallak JE, Honer HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russel BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU. Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. *Am J Psychiatr* 2017 Mar 1;174(3):216-29.

Huang T, Larsen KT, Jepsen JRM, Møller NC, Thorsen AK, Mortensen EL, Andersen LB. Effects of an obesity intervention program on cognitive function in children: A randomized controlled trial. *Int J Obesity* 2015;23(10):2101-8.

Ishøy PL, Fagerlund B, Broberg BV, Bak N, Knop FK, Glenthøj BY, Ebdrup BH. No Cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. *Acta Psychiatr Scand* 2017 Jul;136(1):52-62.

Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH. Effect of GLP-1 Receptor Agonist Treatment on Body weight in Obese Antipsychotic-treated Patients with Schizophrenia: a Randomized, Placebo-controlled Trial. *Diabetes Obes Metab* 2017 Feb ;19(2) :162-71.

Ishøy PL, Knop FK, Broberg BV, Baandrup L, Fagerlund B, Jørgensen NR, Andersen UB, Rostrup E, Glenthøj BY, Ebdrup BH. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist – protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. *BMJ Open* 2014 Jan 8;4(1):e004158.



Jalbrzikowski M et al. ENIGMA Clinical High Risk Group. Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis. *JAMA Psychiatr* 2021 Jul 1;78(7):753-66.

Jennum P, Baandrup L, Tønnesen P, Ibsen R, Kjellberg J. Mortality and use of psychotropic medication in sleep apnoea patients: a population-wide register-based study. *Sleep Med* 2018 Mar;43:19-24.

Jennum PJ, Baandrup L, Iversen HK, Ibsen R, Kjellberg J. Mortality and use of psychotropic medication in patients with stroke: a population-wide, registerbased study. *BMJ Open* 2016 Mar 8;6(3):e010662. Doi: 10.1136/bmjopen-2015-010662.

Jennum PJ, Baandrup L, Ibsen R, Kjellberg J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. *Eur Neuropsychopharmacol* 2015 Nov;25(11):1906-13.

Jensen KG, Correll CU, Rudå D, Klauber DG, Decara MS, Fagerlund B, Jepsen JRM, Eriksson E, Fink-Jensen A, Pagsberg AK. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. *J Am Acad Child Adolesc Psychiatr* 2019;58(11):1062-78.

Jensen KG, Gärtner S, Correll CU, Rudå D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JR, Fink-Jensen A, Juul K, Pagsberg AK. Change and dispersion of QT interval during treatment with quetiapine Extended Release versus aripiprazole in children and adolescents with first-episode psychosis: Results from the TEA trial. *Psychopharmacol (Berl)* 2018 Mar;235(3):681-93.

Jensen KG, Correll CU, Rudå D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JR, Fink-Jensen A, Pagsberg AK. Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial. *J Clin Psychiatry* 2017 Sep/Oct;78(8):e1035-e1046. doi: 10.4088/JCP.15m10479.

Jensen MH\*, Bak N\*, Rostrup E, Nielsen MØ, Pantelis C, Glenthøj BY, Ebdrup BH, Fagerlund B. The impact of schizophrenia and intelligence on the relationship between age and brain volume. *Schizophr Res Cogn* 2019 Mar;15:1-6 eCollection \*shared first authorship

Jepsen JRM, Rydkjaer J, Fagerlund B, Pagsberg AK, Glenthøj BY, Oranje B. Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorder or attention-deficit/hyperactivity disorder. *Psychol Med* 2018;48(4):604-16.

Jessen K, Mandl RCW, Fagerlund B, Bojesen KB, Raghava JM, Obaid HG, Jensen MB, Johansen LB, Nielsen MØ, Pantelis C, Rostrup E, Glenthøj BY, Ebdrup BH. Patterns of cortical structures and cognition in antipsychotic-naïve patients with first-episode schizophrenia: A partial least squares correlation analysis. *Biol Psychiatr: Cogn Neurosc and Neuroimag* 2019 May;4(5):444-53.

Jessen K, Rostrup E, Mandl RCW, Nielsen MØ, Bak N, Fagerlund B, Glenthøj BY, Ebdrup BH. Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after six weeks of dopamine D2/3 receptor antagonist treatment. *Psychol Med* 2019 Apr;49(5):754-63.

Jørgensen M, Mainz J, Svendsen ML, Nordentoft M, Voldsgaard I, Baandrup L, Bartels P, Johnsen SP. Improving quality of care among patients hospitalized with schizophrenia: A nationwide initiative.

BJPsych Open 2015 (1);48-53.

Kaalund-Brok K, Houmann TB, Hebsgaard MB, Lauritsen MBG, Lundstrøm LH, Grønning H, Darlind L, Reinert-Petersen S, Petersen MAA, Jepsen JRM, Pagsberg AK, Plessen KJ, Rasmussen HB, Jeppesen P. Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD. *PLoS One* 2021 Oct 21;16(10):e0253727.

Kahn RS, van Rossum IW, Leucht S, McGuire P, Lewis SW, Lebayer M, Arango C, Dazzan P, Drake R, Heres S, Díaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthøj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE, for the OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. *Lancet Psychiatr* 2018 Oct;5(10):797-807.

Kenborg L, Andersen EW, Duun-Henriksen AK, Jepsen JRM, Doser K, Dalton SO, Bidstrup PE, Krøyer A, Frederiksen LE, Johansen C, Østergaard JR, Hove H, Sørensen SA, Riccardi VM, Mulvihill JJ, Winther JF. Psychiatric disorders in individuals with neurofibromatosis 1 in Denmark: A nationwide register-based cohort study. *Am J Med Genet A* 2021;185(12):3706-16.

Kerins S et al (PSYSCAN Consortium). Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. *Front Psychiatr* 2022 Mar 16;13:828376. eCollection 2022.

Kjaerby C, Broberg BV, Kristiansen U, Dalby NO. Impaired GABAergic inhibition in prefrontal cortex of early postnatal phencyclidine (PCP) treated rats. *Cereb Cortex* 2014 Sep;24(9):2522-32.

Kjaergaard MF, Videbech P, Nørnbæk J, Ebdrup BH. Gamma-Hydroxybutyric acid-induced organic delirium complicated by polydrug use successfully treated with electroconvulsive therapy. A case report. *J Med Case Rep* 2021 Dec;15(1):596.

Kjaersdam Telléus G, Fagerlund B, Jepsen JRM, Bentz M, Christiansen E, Valentin JB, Thomsen PH. Are Weight Status and Cognition Associated? An Examination of Cognitive Development in Children and Adolescents with Anorexia Nervosa 1 Year after First Hospitalisation. *Eur Eat Disord Rev* 2016 Sep;24(5):366-76.

Kjaersdam Telléus G, Jepsen JRM, Bentz M, Christiansen E, Jensen SOW, Fagerlund B, Thomsen PH. Cognitive Profile of Children and Adolescents with Anorexia Nervosa. *Eur Eat Disord Rev* 2015;23(1):34-42.

Klaerke LR, Baandrup L, Fagerlund B, Ebdrup BH, Pantelis C, Glenthøj BY, Nielsen MØ. Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia. *Eur Psychiatr* 2019;62:130-7.

Knudsen CB, Hemager N, Greve AN, Lambek R, Andreassen AK, Veddum L, Brandt JM, Gregersen M, Krantz MF, Søndergaard A, Steffensen NL, Birk M, Stadsgaard HB, Ohland J, Burton BK, Jepsen JRM, Thorup AAE, Nordentoft M, Mors O, Bliksted VF. *JAMA Psychiatr* 2022 6:e220465. Online ahead of print.

Krakauer K, Nordentoft M, Glenthøj BY, Raghava JM, Nordholm D, Randers L, Glenthøj LB, Ebdrup BH, Rostrup E. White matter maturation during 12 months in individuals at ultra-high-risk for psychosis. *Acta Psych Scand* 2018;137(1):65-78.

Krakauer K, Ebdrup BH, Glenthøj BY, Raghava JM, Nordholm D, Randers L, Rostrup E, Nordentoft M.

Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms. *Psychol Med* 2017;47(15):2689-707.

Kristensen S, Holmskov J, Baandrup L, Videbech P, Bonde M, Mainz J. Evaluating the implementation in mental health clinical research: a descriptive review in comparison with clinician-rated outcome measures. *Int J Quality Health Care* 2021, in press.

Kristensen S, Mainz J, Baandrup L, Bonde M, Videbech P, Holmskov J, Bech P. Conceptualizing patient-reported outcome measures for use within two Danish psychiatric clinical registries: description of an iterative co-creation process between patients and healthcare professionals. *Nord J Psychiatr* 2018 Aug;72(6):409-19.

Kristensen TD, Glenthøj LB, Raghava JM, Syeda W, Mandl RCW, Wenneberg C, Krakauer K, Fagerlund B, Pantelis C, Glenthøj BY, Nordentoft M, Ebdrup BE. Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis. *Schizophr Res* 2021 nov;237:192-201.

Kristensen TD, Glenthøj LB, Ambrosen K, Syeda W, Raghava JM, Krakauer K, Wenneberg C, Fagerlund B, Pantelis C, Glenthøj BY, Nordentoft M, Ebdrup BH. Global Fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra-high risk for psychosis. *Acta Psychiatr Scand* 2021 Nov;144(5):448-63.

Kristensen TD, Ebdrup BH, Hjorthøj C, Mandl RCW, Raghava JM, Jepsen JRM, Fagerlund B, Glenthøj LB, Wenneberg C, Krakauer K, Pantelis C, Glenthøj BY, Nordentoft M. No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis – A Randomized Clinical Trial. *Front Psychiatry* 2020 Aug 28;11:873.

Kristensen TD, Mandl RCW, Raghava JM, Jessen K, Jepsen JRM, Fagerlund B, Glenthøj LB, Wenneberg C, Krakauer K, Pantelis C, Nordentoft M, Glenthøj BY, Ebdrup BH. Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis. *Human Brain Mapping* 2019 Dec 15;40(18):5185-201.

Kristensen TD, Mandl RCW, Jepsen JRM, Rostrup E, Glenthøj L, Nordentoft M, Glenthøj BY, Ebdrup. Non-pharmacological modulation of cerebral white matter organization: a systematic review of non-psychiatric and psychiatric studies. *Neurosci & Biobehav Rev* 2018;88:84-97.

Kruiper C, Glenthøj B, Oranje B. Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication. *Neuropsychopharm* 2019 May;44(6):1062-7.

Kruiper C, Fagerlund B, Nielsen MØ, Düring S, Jensen MH, Ebdrup BH, Glenthøj BY, Oranje B. Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients. *Psychol Med* 2019 Apr;49(5):868-75.

Köhler O, Horsdal HT, Baandrup L, Mors O, Gasse C. Association between Global Assessment of Functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia. *Clin Epidemiol* 2016;8:323–32.

Köse G, Jessen K, Ebdrup BH, Nielsen MØ. Associations between cortical thickness and auditory verbal hallucinations in patients with schizophrenia: A systematic review. *Psychiatry Research: Neuroimaging* 2018;282:31-9.

LaBianca S, Jensen R, van den Maagdenberg AMJM, Baandrup L, Bendtsen L. Familial Hemiplegic Migraine and Recurrent Episodes of Psychosis: A Case Report. *Headache* 2015;55(7):1004-7.

Larsen LQ, Schnor H, Tersbøl BP, Ebdrup BH, Nordsborg NB, Midtgaard J. The impact of exercise training complementary to early intervention in patients with first-episode psychosis: a qualitative sub-study from a randomized controlled feasibility trial. *MBC Psychiatr* 2019 Jun 21;19(1):192. doi: 10.1186/s12888-019-2179-3.

McKenzie E, Matkin L, et al. ICHOM Psychosis working group. Developing an International Standard Set of Patient-Reported Outcome Measures for Psychotic Disorders. *Psychiatric Services* 2021.

Legind CS, Faurholt-Jepsen M, Ebdrup BH, Anhøj S, Benros ME. Digital innovation giver nye perspektiver i psykiatrien. *UFL* 2022;184:V08210649.

Legind CS, Broberg B, Brouwer R, Mandl RCW, Ebdrup BH, Anhøj SJ, Jensen MH, Hilker R, Fagerlund B, Hulshoff HE, Glenthøj BY, Rostrup E. Heritability of cerebral blood flow and the correlation to schizophrenia spectrum disorders: A pseudo-continuous arterial spin labelling twin study. *Schizophr Bull* 2019 Oct 24;45(6):1231-41.

Legind CS, Broberg B, Mandl R, Brouwer R, Anhøj S, Hilker R, Jensen M, McGuire P, Pol H, Fagerlund B, Rostrup E, Glenthøj B. Heritability of cerebral glutamate levels and their association to schizophrenia spectrum disorder: A  $^1\text{H}$ -spectroscopy twin study. *Neuropsychopharmacol* 2019;44(3):581-89.

Lemvigh CK, Glenthøj BY, Fagerlund B. A nation-wide twin study of social cognition in schizophrenia spectrum disorders. Brief communication. *Schizophrenia Open* 2022;8:12.

Lemvigh CK, Karantonis JA, Furlong LS, Carruthers SP, Pantelis C, Rossell SL, Van Rheenen TE. Characterization and interrelationships of theory of mind, socially competitive emotions and affective empathy in bipolar disorder. *Br J Clin Psychol* 2022 Mar;61(1):76-92.

Lemvigh C, Brouwer R, Hilker R, Anhøj S, Baandrup L, Pantelis C, Glenthøj B, Fagerlund B. The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study. *Psychol Medicine* 2021 Online ahead of print.

Lemvigh CK. Genetiske og miljømassige risikofaktorer for skizofreni: Et nationalt tvillingestudie med fokus på kognition. *Dansk Psykologforenings fagmagasin*. 2020.  
<https://infolink2020.dk/PsyNyt/Dokumenter/doc/19270.pdf>

Lemvigh CK, Brouwer RM, Sahakian BJ, Robbins TW, Johansen LB, Legind CS, Anhøj SJ, Hilker R, Hulshoff Pol HE, Ebdrup BH, Pantelis C, Glenthøj BY, Fagerlund B. Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins. *Schizophr Bull Open* Nov 2020.

Lemvigh CK, Brouwer RM, Pantelis C, Jensen MH, Hilker RW, Legind CS, Anhøj SJ, Robbins TW, Sahakian BJ, Glenthøj BY, Fagerlund B. Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nationwide twin study. *Psychol Med* 2020 Aug 11;1-14.  
Doi:10.1017/S0033291720002858. Online ahead of print. PMID:32779562.

Lemvigh CK, Jepsen JRM, Fagerlund B, Pagsberg A, Glenthøj B, Rydkjaer J, Oranje B. Auditory Sensory Gating in Young Adolescents with Early-onset Psychosis: A Comparison with Attention deficit/Hyperactivity disorder. *Neuropsychopharm* 2020;Mar;45(4):649-55.

Lethinen EK, Ucar E, Glenthøj BY, Oranje B. Effects of melatonin on prepulse inhibition, habituation and sensitization of the human startle reflex in healthy volunteers. *Psychiatr Res* 2014 May 30;216(3):418-23.

Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenthøj B, Leboyer M, Leweke M, Lewis S, McGuire P, Meyer-Lindenberg A, Rujescu D, Kapur S, Kahn RS, Sommer IE. The Optimization of Treatment of Management of Schizophrenia in Europe (OPTiMiSE) trial: Rationale for its methodology and a review of an effectiveness of switching antipsychotics. *Schizophr Bull* 2015;41(3):549-58.

Low AM, Vangkilde S, le Sommer J, Fagerlund B, Glenthøj B, Jepsen J, Bundesen C, Petersen A, Habekost T. Visual attention in adults with Attention-Deficit/Hyperactivity Disorder before and after stimulant treatment. *Psych Med* 2019 Nov;49(15):2617-25.

Low AM, le Sommer J, Vangkilde S, Fagerlund B, Glenthøj B, Sonuga-Barke E, Habekost T, Jepsen JRM. Delay aversion and Executive Functioning in adults with Attention-Deficit/Hyperactivity Disorder: Before and after stimulant treatment". *J Neuropsychopharmacol* 2018 Nov 1;12(11):997-1006.

Madsen GF, Bilenberg N, Jepsen JRM, Glenthøj BY, Cantio C, Oranje B. Normal P50 gating in children with autism, yet attenuated P50 amplitude in the Asperger subcategory. *Autism Res* 2015 Aug;8(4):371-8.

Madsen GF, Bilenberg N, Cantio C, Oranje B. Increased Prepulse Inhibition and Sensitization of the Startle Reflex in Autistic Children. *Autism Res* 2014;7(1):94-103.

Madsen HK, Nordholm D, Krakauer K, Randers L, Nordentoft M. Psychopathology and social functioning of 42 subjects from a Danish ultra high-risk cohort. *Early Interv Psychiatr* 2018 Dec;12(6):1181-7.

Madsen KS, Johansen LB, Thompson W, Siebner HR, Jernigan TL, Baaré WFC. Maturational trajectories of white matter microstructure underlying the right presupplementary motor area reflect individual improvements in motor response cancellation in children and adolescents. *Neuroimage* 2020 Oct 15;220:117105.

Marteene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, Ebdrup BH, Firth J, Siskind D. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. *Expert Opin Drug Saf* 2019 Dec;18(12):1149-60.

Martinuzzi E, Barbosa S, Daoudlarian D, Ali WBH, Gilet C, Fillatre L, Khalfallah O, Troudet R, Jamain S, Fond G, Sommer I, Leucht S, Dazzan P, McGuire P, Arango C, Diaz-Caneja CM, Fleischhacker W, Rujescu D, Glenthøj B, Winter I, Kahn RS, Yolken R, Lewis S, Drake R, Davidovic L, Leboyer M, Glaichenhaus N;OPTiMiSE Study Group. Correction: Stratification and prediction of remission in first-episode psychosis patients: The OPTiMiSE Study Group. *Transl Psychiatr* 2019 Jun 21;9(1):171.

Martinuzzi E, Barbosa S, Daoudlarian D, Ali WBH, Gilet C, Fillatre L, Khalfallah O, Troudet R, Jamain S, Fond G, Sommer I, Leucht S, Dazzan P, McGuire P, Arango C, Diaz-Caneja CM, Fleischhacker W, Rujescu D, Glenthøj B, Winter I, Kahn RS, Yolken R, Lewis S, Drake R, Davidovic L, Leboyer M, Glaichenhaus N;OPTiMiSE Study Group. Stratification and prediction of remission in first-episode psychosis patients: The OPTiMiSE Study Group. *Transl Psychiatr* 2019 Jan 17;9(1):20.

Menghini-Müller S, Studerus E, Ittig S, Heitz U, Egloff L, Andreou C, Valmaggia LR, Kempton MJ, van der Gaag M, de Haan L, Nelson B, Barrantes-Vidal N, Nordentoft M, Ruhrmann S, Sachs G, Rutten BP, Os JV, Riecher-Rössler A; EU-GEI High Risk Study Group, McGuire P, Valmaggia LR, Kempton MJ, Calem M, Tognin

S, Modinos G, de Haan L, vander Gaag M, Velthorst E, Kraan TC, van Dam DS, Burger N, Nelson B, McGorry P, Amminger GP, Pantelis C, Politis A, Goodall J, Riecher-Rössler A, Borgwardt S, Rapp C, Ittig S, Studerus E, Smieskova R, Bressan R, Gadelha A, Brietzke E, Asevedo G, Asevedo E, Zugman A, Barrantes-Vidal N, Domínguez-Martínez T, Raddioppi A, Cristóbal-Narváez P, Kwapil TR, Monsonet M, Kazes M, Daban C, Bourgin J, Gay O, Mam-Lam-Fook C, Krebs MO, Nordholm D, Randers L, Krakayer K, Glenthøj L, Glenthøj B, Nordentoft M, Ruhrmann S, Gebhard D, Arnhold J, Klosterkötter J, Sachs G, Lasser I, Winklbaur B, Delespaul PA, Rutten BP, van Os J. Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI Study. *Eur Psychiatr* 2019 Jun;59:52-9.

Melau M, Harder S, Jeppesen P, Hjorthøj C, Jepsen JRM, Thorup A, Nordentoft M. The association between working alliance and clinical and functional outcome in a cohort of 400 patients with first-episode psychosis: a cross-sectional study. *J Clin Psychiatr* 2015;76(1):83-90.

Merritt K, Perez-Iglesias R, Sendt KV, Goozee R, Jauhar S, Pepper F, Barker GJ, Glenthøj B, Arango C, Lewis S, Kahn R, Stone J, Howes O, Dazzan P, McGuire P, Egerton A. Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. *NPJ Schizophr* 2019 Aug 1;5(1):12.

Meteran H, Vindbjerg E, Uldall SW, Glenthøj B, Carlsson J, Oranje B. Startle habituation, sensory and sensorimotor gating in trauma-affected refugees with posttraumatic stress disorder. *Psychological Med* 2019 Mar;49(4):581-9.

Midtgaard J, Schnor H, Bjerre ED, Jespersen T, Jelsøe N, Frølund N, Seier S, Rønbørg JW, Nordsborg NB, Ebdrup BH. Exercise training complementary to specialised early intervention in patients with First-episode psychosis: a feasibility randomised trial. *Pilot Feasibility Stud* 2021 Aug 19;7(1):162.

Modinos G, Kempton MJ, Tognin S, Calem M, Porffy L, Antoniadis M, Mason A, Azis M, Allen P, Nelson B, McGorry P, Pantelis C, Riecher-Rössler A, Borgwardt S, Bressan R, Barrantes-Vidal N, Krebs MO, Nordentoft M, Glenthøj B, Ruhrmann S, Sachs G, Rutten B, van Os J, de Haan L, Velthorst E, van der Gaag M, Valmaggia LR, McGuire P for the EU-GEI High Risk Study Group. Association of Adverse Outcomes With Emotion Processing and its Neural Substrate in Individuals at Clinical High Risk for Psychosis. *JAMA Psychiatr* 2020 Feb 1;77(2):190-200.

Mohammadzadeh P, Rosenberg JB, Vinding R, Jepsen JRM, Lindberg U, Følsgaard N, Sørensen ME, Sulaiman D, Bilenberg N, Raghava JM, Fagerlund B, Vestergaard M, Pantelis C, Stockholm J, Chawes B, Larsson H, Glenthøj BY, Bønnelykke K, Ebdrup BH, Bisgaard H. Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomized controlled trial – the COPSYCH study protocol. *BMJ Open* 2022 Feb 1. <http://bmjopen.bmj.com>

Mohr GH, Barcella CA, Coello K, Baandrup L, Knop FK. Dyslipidæmi ved psykisk lidelse. *UFL* 2022 Mar 7;184(10):V05210439.

Mortensen CB, Poulsen LM, Andersen-Ranberg NC, Perner A, Lange T, Estrup S, Ebdrup BH, Egerod I, Rasmussen BS, Hästbacka J, Caballero J, Citero G, Morgen MPG, Samuelson K, Mathiesen O. Mortality and HRQOL in ICU patients with delirium: Protocol for 1-year follow-up of AID-ICU Trial. *Acta Anaest Scand* 2020 Nov;64(10):1519-25.

Mortensen EL, Flensborg –Madsen T, Molbo D, Fagerlund B, Christensen U, Lund R, Osler M, Avlund K. The Relationship between cognitive ability and demographic factors in late midlife. *J Aging Health* 2014;26,1:37-53.

Mucci A, Vignapiano A, Bitter I, Austin SF, Delouche C, Dollfus S, Erfurth A, Fleischhacker WW, Giordano GM, Gladyshev I, Glenthøj B, Gütter K, Hofer A, Hubenák J, Kaiser S, Libiger J, Melle I, Nielsen MØ, Papsuev O, Rybakowski JK, Sachs G, Úcok A, Wojciak P, Galderisi S. A large European, multicenter validation study of the Brief Negative Symptom Scale. *Eur Neuropsychopharm* 2019 Aug;29(8):947-59.

Mucci A, Úcok A, Nielsen MØ. Electrophysiological and Neuroimaging Research on Negative Symptoms: Future Challenges. *Clin EEG and Neurosci (ECNS)* 2018;49:3-5.

Nicodemus KK et al. Schizophrenia Psychiatric Genome-wide Association Study (GWAS) Consortium; Wellcome Trust Case Control Consortium 2. Variability in working memory performance explained by epistasis vs polygenetic scores in the ZNF804A pathway. *JAMA Psychiatr* 2014 Jul 1;71(7):778-85.

Nielsen MØ, Kristensen TD, Bojesen KB, Glenthøj BY, Lemvig CK, Ebdrup BH. Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive symptoms in Patients with First Episode Psychoses. *Frontiers* 2022, Mar 17. <https://doi.org/10.3389/fpsyt.2022.834333> eCollection.

Nielsen MØ, Rostrup E, Hilker R, Legind C, Anhøj S, Robbins TW, Sahakian BJ, Fagerlund B, Glenthøj B. Reward processing as an Indicator of Vulnerability or Compensatory Resilience? Results from a Twin Study. *Biol Psychiatr Global Open Science* 2022,Jan 21. ONLINE VERSION

Nielsen MØ, Milting K, Brandt-Christensen AM, Ebdrup BH. Increased use of coercive procedures and prolonged hospitalization in compulsory admitted psychotic patients, who refuse antipsychotic medication. *Nord J Psychiatr* 2020 May-Jul;74(5):323-6.

Nielsen MO, Rostrup E, Broberg BV, Wulff S, Glenthøj BY. Negative symptoms and reward disturbances in schizophrenia before and after antipsychotic monotherapy. *Clin EEG & Neurosci* 2018 Jan;4(1):36-45.

Nielsen MO, Rostrup E, Wulff S, Glenthøj B, Ebdrup BH. Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. *JAMA Psychiatr* 2016 Feb 1;73(2):121-8.

Nordgaard J, Jessen K, Sæbye D, Parnas J. Variability in clinical diagnoses during the ICD-8 and ICD-10 era. *Soc Psychiatr Psychiatric Epidemiol* 2016;51(9):1293-9.

Nordholm D, Hjorthøj C, Mondelli V, Krakauer K, Randers L, Dazzan P, Nordentoft M. Are attenuated positive symptoms and cortisol levels associated? *Schizophr Bull* 2021 Feb;228:621-3.

Nordholm D, Rostrup E, Randers L, Mondelli V, Nielsen MØ, Randers L, Nielsen MØ, Wulff S, Nørbak-Emig H, Broberg BV, Krakauer K, Dazzan P, Zunszain PA, Nordentoft M, Glenthøj B. Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients *Psychoneuroendocrinol* 2018 Jun;92:72-80.

Nordholm D, Poulsen HE, Hjorthøj C, Randers L, Nielsen MØ, Wulff S, Krakauer K, Nørbak-Emig H, Henriksen T, Glenthøj B, Nordentoft M. Systemic oxidative DNA og RNA damage are not increased during early phases of psychosis: A case control study. *Psychiatry Res* 2016;241:201-6.

Nudel R, Christiani CAJ, Ohland J, UddinMJ, Hemager N, Ellersgaard D, Spang KS, Burton BK, Greve AN, Gantriis DL, Bybjerg-Grauholm J, Jepsen JRM, Thorup AAE, Mors O, Werge T, Nordentoft M. Quantitative genome-wide association analyses of receptive language in the Danish High Risk and Resilience Study. *BMC Neurosci* 2020 Jul 7;21(1):30.

Nudel R, Christiani CAJ, Ohland J, Uddin MJ, Hemager N, Ellersgaard DV, Spang KS, Burton BK, Greve An, Gantriis DL, Bybjerg-Grauholm J, Jepsen JRM, Thorup AAE, Mors O, Nordentoft M, Werge T. Language deficits in specific language impairment, attention deficit/hyperactivity disorder, and autism spectrum disorder: An analysis of polygenic risk. *Autism Res* 2020 Mar;13(3):369-81.

Nørbak-Emig H, Pinborg LH, Raghava JM, Svarer C, Baaré WC, Allerup P, Friberg L, Rostrup E, Glenthøj BY, Ebdrup BH. Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment. *World J Biol Psychiatr* 2017 Oct;18(7):539-49.

Nørbak-Emig H, Ebdrup BH, Fagerlund B, Svarer C, Rasmussen H, Friberg L, Allerup PN, Rostrup E, Pinborg LH, Glenthøj BY. Frontal D2/3 receptor availability in schizophrenia patients before and after their first antipsychotic treatment: Relation to cognitive functions and psychopathology. *Int J Neuropsychopharm* 2016 Apr 29;19(5). pii: pyw006. doi: 10.1093/ijnp/pyw006. Print 2016 May.

Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthøj BY. Selective attention and Mismatch Negativity in Antipsychotic-Naïve, First-Episode Schizophrenia Patients Before and After Six months of Antipsychotic Monotherapy. *Psychol Med* 2017 Sep;12:2155-65.

Oranje B, Glenthøj BY. Clonidine Normalizes Levels of P50 Gating in Patients with Schizophrenia on Stable Medication. *Schizophr Bull* 2014;40:1022-9.

Ong HL, Isvoranu AM, Schirmbeck F, McGuire P, Valmaggia L, Kempton MJ, van der Gaag M, Riecher-Rössler A, Bressan RA, Barrantes-Vidal N, Nelson B, Amminger GP, McGorry P, Pantelis C, Krebs MO, Nordentoft M, Glenthøj B, Ruhrmann S, Sachs G, Rutten BPF, van Os J, de Haan L, Borsboom D; EU-GEI High Risk Study. Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. *Schizophr Bull* 2021 Jul 8;47(4):1018-28.

Osler M, Rostrup E, Nordentoft M, Lykke Mortensen E, Bruunsgaard H, Fagerlund B. Influence of early life characteristics on psychiatric admissions and impact of psychiatric disease on inflammatory biomarkers and survival: a Danish cohort study. *World Psychiatr* 2015 Oct;14(3):364-5.

Pagsberg AK, Uhre C, Uhre V, Pretzmann L, Christensen SH, Thoustrup C, Clemmensen I, Gudmandsen AA, Korsbjerg NLJ, Mora-jensen ARC, Ritter M, Thorsen ED, Halberg KSVH, Bugge B, Staal N, Ingstrup HK, Moltke BB, Kloster AM, Zoega PJ, Mikkelsen MS, Harboe GS, Larsen KF, Clemmensen LKH, Lindschou J, Jakobsen JC, Engstrøm J, Gluud C, Siebner HR, Thomsen PH, Hybel K, Verhulst F, Jeppesen P, Jepsen JRM, Vangkilde S, Olsen MH, Hagstrøm J, Lønfeldt NN, Plessen KJ. Family-based cognitive behavioural therapy versus family-based relaxation therapy for obsessive-compulsive disorder in children and adolescents: protocol for a randomized clinical trial (the TECTO trial). *MBC Psychiatr* 2022 Mar 19;22(1):204.

Pagsberg AK, Krogmann A, Jeppesen P, von Hardenberg L, Klauber DG, Jensen KG, Rudå D, Decara MS, Jepsen JRM, Fagerlund B, Fink-Jensen A, Correll CU, Galling B. Early Antipsychotic Non-response as a Predictor of Non-response and Non-remission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial. *Am Acad Child Adolesc Psychiatr* 2022 Jan 7;doi: 10.1016/j.jaac.2021.11.021. Online ahead of print

Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EAS, Lauritsen MGB, Bilenberg N, Stenstrom AD, Nyvang L, Madsen S, Werge TM, Lange T, Gluud C, Skoog M, Winkel P, Jepsen JRM, Fagerlund B, Corell CU, Fink-Jensen A. Quetiapine extended release versus



aripiprazole in children and adolescents with first episode psychosis: a double-blind randomised Tolerability and Efficacy of Antipsychotics (TEA) trial. *Lancet Psychiatr* 2017 Aug;4(8):605-18.

Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EAS, Lauritsen MGB, Bilenberg N, Stenstrom AD, Pedersen J, Nyvang L, Madsen S, Lauritsen MB, Vernal DL, Thomsen PH, Paludan J, Werge TM, Winge K, Juul K, Gluud C, Skoog M, Wetterslev J, Jepsen JR, Correll CU, Fink-Jensen A, Fagerlund B. Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. *BMC Psychiatr* 2014;14:199.

Pandit R, Cianci D, Ter Hark SE, Winter-van Rossum I, Ebdrup BH, Broberg BV, Garcia-Portilla MP, Bobes J, Vinkers CH, Kahn RS, Guloksuz S, Huitema ADR, Luyks JJ. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). *Acta Psychiatr Scand* 2019 Sep;140(3):283-90.

Pauls MH, Binnie LR, Benjamin P, Betteridge S, Clarke B, Dillon MPK, Ghatala R, Hainsworth FAH, Howe FA, Khan U, Kruuse C, Madigan JB, Moynihan B, Patel B, Pereira A, Rostrup E, Shatya ABY, Spilling CA, Trippier S, Williams R, Young R, Barrick TR, Isaacs JD, Hainsworth AH. *Alzheimers Dement* 2022 Feb 8. Online ahead of print.

Pollak TA, Kempton MJ, Lyegbe C, Vincent A, Irani SR, Coutinho E, Menassa DA, Jacobseon L, De Haan L, Ruhrmann S, Sachs G, Riecher-Rössler A, Krebs MO, Amminger P, Glenthøj B, Barrantes-Vidal V, van Os J, Rutten BPF, Bressan RA, van der Gaag M, EU GEI RISK STUDY. Clinical, Cognitive and Neuroanatomical Associations of Serum NMDAR Autoantibodies in People at Clinical High Risk for Psychosis. *Molecular Psychiatr* 2021 Jun;26(6):2590-604.

Raghava JM, Mandl RCW, Nielsen MØ, Fagerlund B, Glenthøj BY, Rostrup E, Ebdrup BH. Multimodal assessment of white matter microstructure in antipsychotic-naïve schizophrenia patients and confounding effects of recreational drug use. *Brain Imaging Behav* 2021 Febr;15(1):36-48.

Randau M, Oranje B, Miyakoshi M, Makeig S, Fagerlund B, Glenthøj B, Bak N. Attenuated mismatch negativity in patients with first-episode antipsychotic-naïve schizophrenia using a source-resolved method. *NeuroImage: Clinical* 2019;22:101760. doi: 10.1016/j.nicl.2019.101760.

Randers L, Jepsen JRM, Fagerlund B, Nordholm D, Krakauer K, Hjorthøj C, Glenthøj B, Nordentoft M. Generalized Neurocognitive Impairment in Individuals at Ultra-High Risk for Psychosis: The Possible Key Role of Slowed Processing Speed. *Brain & Behaviour* 2021 Mar;11(3):e01962.

Randers, Fagerlund B, Jepsen JRM, Nordholm D, Krakauer K, Hjorthøj C, Glenthøj B, Nordentoft M. Interview and Questionnaire Assessment of Cognitive Impairment in subjects at Ultra-High Risk for Psychosis: Associations with Cognitive Test Performance, psychosocial Functioning, and Positive Symptoms. *Psychiatr Res* 2020 Dec;294:113498.

Randers L, Jepsen JRM, Fagerlund B, Nordholm D, Krakauer K, Hjorthøj C, Glenthøj B, Nordentoft M. Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. *Psychiatr Res* 2020 Aug;290.

Ranning A, Laursen T, Agerbo E, Thorup A, Hjorthøj C, Jepsen JRM, Nordentoft M. School performance from primary education in the adolescent offspring of parents with schizophrenia and bipolar disorder- a national, register-based study. *Psychol Med* 2018 Sep;48(12):1993-2000.

Rask L, Bendix L, Harbo M, Fagerlund B, Mortensen EL, Lauritzen MJ, Osler M. Cognitive Change during the life Course and Leukocyte Telomere Length in Late Middle-Aged Men. *Front Aging Neurosci* 2016 Dec 9;8:300.

Rasmussen H, Frøkjær V, Hilker RW, Madsen J, Anhøj S, Oranje B, Pinborg LH, Glenthøj B, Knudsen GM. Low frontal serotonin 2A receptor binding is a state marker for schizophrenia? *Eur Neuropsychopharmacol* 2016;26(7):1248-50.

Rasmussen H, Ebdrup BH, Oranje B, Pinborg LH, Knudsen GM, Glenthøj B. Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients. *Int J Neuropsychopharmacol* 2014 Nov;17(11):1729-36.

Rasmussen JØ, Jennum P, Linnet K, Glenthøj BY, Baandrup L. Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial. *MBC Psychiatr* 2021 Aug;21(1):404. PMID:34391393 Free PMC article.

Ringqvist Å, Bech P, Glenthøj B, Petersen E. Acute and Long-term Psychiatric Side Effects of Mefloquine: A Follow-up on Danish Adverse Event Reports. *Travel Medicine and Infectious Disease* 2015;13(1):80-8.

Rohde C, Polcwiartek C, Kragholm K, Ebdrup BH, Siskind D, Nielsen J. Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. *Acta Psychiatr Scand* 2018;137(1):47-53.

Rudaa D, Jensen KG, Decara MS, Klauber DG, Fagerlund B, Møllegaard JR, Linnet K, Werge T, Correll CU, Fink-Jensen A, Jürgens G, Pagsberg AK. CYP2D6 Genotyping and Antipsychotic-Associated Extrapyrmidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis. *J Clin Psychopharm* 2021 Nov-Dec;41(6):667-72.

Rudaa D, Einarsson G, Matthiassen J, Correll C, Jensen K, Klauber D, Richard C, Andersen AS, Krøigaard S, Moellegaard Jepsen JR, Fagerlund B, Winge K, Clemmensen L, Pagsberg AK, Paulsen RR, Fink-Jensen A. Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: A pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. *Child Adolesc Ment Health* 2020 May;25(2):79-94.

Rybner A, Jessen ET, Mortensen MD, Larsen SN, Grossman R, Bilenberg N, Cantio C, Jepsen JRM, Weed E, Simonsen A, Fusaroli R. Vocal markers of autism: Assessing the generalizability of machine learning models. *Autism Res* 2022 Apr 6. Online ahead of print.

Rydkjaer J, Jepsen JRM, Glenthøj B, Fagerlund B, Pagsberg AK, Oranje B. Do young adolescents with first-episode psychosis or ADHD show sensorimotor gating deficits? *Psychol Med* 2020 Mar;50(4):607-15.

Rydkjaer J, Jepsen JRM, Pagsberg AK, Fagerlund B, Glenthøj BY, Oranje B. Mismatch negativity and P3a amplitude in young adolescents with first episode psychosis: a comparison with ADHD. *Psychol Med* 2017 Jan;47(2):377-88.

Sass L, Bjarnadóttir E, Stokholm J, Chawes B, Vinding RK, Mora-Jensen AC, Thorsen J, Noergaard S, Ebdrup BH, Jepsen JRM, Fagerlund B, Bønnelykke K, Lauritzen L, Bisgaard H. Fish Oil Supplementation in Pregnancy and Neurodevelopment in Childhood – A Randomized Clinical Trial. *Child Dev* 2021 Jul;92(4):1624-35.

Schirmbeck F, van der Burg NC, Blankers M, Vermeulen JM, McGuire P, Valmaggia LR, Kempton MJ, van der Gaag M, Riecher-Rössler A, Bressan RA, Barrantes-Vidal N, Nelson B, Amminger GP, McGorry P, Pantelis C, Krebs MO, Ruhrmann S, Sachs G, Rutten BPF, van Os J, Nordentoft M, Glenthøj B, EU-GEI High Risk Study Group Authors; Fusar-Poli P, de Haan L. Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-High Risk for Psychosis. *Schizophr Bull* 2022 Jan 21;48(1):100-10.

Schmock H, Vangkilde A, Larsen KM, Fischer E, Birknow MR, Jepsen JR, Olesen C, Skovby F, Plessen KJ, Mørup M, Hulme O, Baaré WF, Didriksen M, Siebner HR, Werge T, Olsen L. The Danish 22q11 research initiative. *BMC Psychiatry* 2015 Sep 17;15(1):220.

Sigvard AK, Nielsen MØ, Gjedde A, Bojesen KB, Fuglø D, Tangmose K, Kumakura Y, Heltø K, Ebdrup BH, Jensen LT, Rostrup E, Glenthøj BY. Dopaminergic Activity in Antipsychotic-naïve Patients Assessed with PET Before and After Partial Dopamine D2-receptor Agonist Treatment: Association with Psychotic Symptoms and Treatment Response. *Biol Psychiatr* 2022 Jan 15;91(2):236-45.

Sinclair D, Oranje B, Razak KA, Siegel SJ, Schmid S. Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models. *Neurosci Biobehav Rev* 2017 May;76:235-53.

Siskind D, Hahn M, Correll C, Fink-Jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant meta-analysis. *Diabetes Obes Metab* 2019 Feb;21(2):293-302.

Soldatos RF, Cearns M, Nielsen MØ, Kollias C, Xenaki LA, Stefanatou P, Ralli I, Dimitrakopoulos S, Hatzimanolis A, Kosteletos I, Vlachos II, Selakovic M, Foteli S, Nianiakas N, Mantonakis L, Triantafyllou TF, Ntigidaki A, Ermiliou V, Voulgaraki M, Psarra E, Sørensen ME, Bojesen KB, Tangmose K, Sigvard AM, Ambrosen KS, Merrit T, Syeda W, Glenthøj BY, Koutsouleris N, Ebdrup BH, Stefanis N. Corrigendum to: Prediction of Early Symptom Remission in Two Independent Samples of First-Episode Psychosis Patients Using Machine learning. *Schizophr Bull* 2022 Jan 21;48(1):283.

Soldatos RF, Cearns M, Nielsen MØ, Kollias C, Xenaki LA, Stefanatou P, Ralli I, Dimitrakopoulos S, Hatzimanolis A, Kosteletos I, Vlachos II, Selakovic M, Fotelli S, Nianiakas N, Mantonakis L, Triantafyllou TF, Ntigidaki A, Ermiliou V, Voulgaraki M, Psarra E, Sørensen ME, Bojesen KB, Tangmose K, Sigvard AM, Ambrosen KS, Merritt T, Syeda W, Glenthøj BY, Koutsouleris N, Pantelis C\*\*, Ebdrup BH\*\*, Stefanis NS\*\*. Prediction of Early Symptom Remission in Two Independent Samples of First-Episode Psychosis Patients Using Machine Learning. *Schizophr Bull* 2022 Jan 21;48(1):122-33.

Sommer JL, Low AM, Jepsen JRM, Fagerlund B, Vangkilde S, Habekost T, Glenthøj B, Oranje B. Effects of Methylphenidate on Mismatch Negativity and P3a Amplitude of Initially Psychostimulant-Naïve, Adult ADHD patients. *Psychol Med* 2021 Jul 5:1-9. Online ahead of print.

Sommer JL, Low Am, Jepsen JRM, Fagerlund B, Vangkilde S, Habekost T, Glenthøj B, Oranje B. Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients. *Eur Neuropsychopharm* 2021 May;46:83-92.

Spang KS, Ellersgaard D, Hemager N, Christiani CJ, Burton BK, Greve AN, Gantriis D, Ohland J, Pedersen MG, Mors O, Nordentoft M, Plessen KJ, Obel C, Jepsen JRM, Thorup AAE. Executive functions in 7-year-old children of parents with schizophrenia or bipolar disorder compared with controls: The Danish High Risk and Resilience Study-VIA 7, a population-based cohort study. *Eur Child Adolesc Psychiatr* 2021 Dec;30(12):1871-84.

Stürup AE, Jensen HD, Dolmer S, Birk M, Albert N, Nielsen M, Hjorthøj C, Eplöv L, Ebdrup BH, Mors O, Nordentoft M. TAILOR – tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. *Trials* 2017;18:445 Open Access <http://rdcu.be/wkpF>

Tangmose K et al. Reward Disturbances in Antipsychotic-Naïve Patients with First-Episode Psychosis and Their Association to Glutamate Levels. *Psychol Med* 2021. Accepted for publ.

Ter Hark SE, Jamain S, Schijven D, Lin BD, Bakker MK, Boland-Auge A, Deleuze JF, Troudet R, Malhotra AK, Gülöksöz S, Vinkers CH, Ebdrup BH, Kahn RS, Leboyer M, Luykx JJ. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). *J Psychopharmacol* 2020 May;34(5):524-31. Doi: 10.1177/0269881120907972

Thomas MB, Raghava JM, Pantelis C, Rostrup E, Nielsen MØ, Jensen MH, Glenthøj BY, Mandl RCW, Ebdrup BH, Fagerlund B. Associations between cognition and white matter microstructure in first-episode antipsychotic-naïve patients with schizophrenia and healthy control: A multivariate pattern analysis. *Cortex* 2021 Jun;139:282-97.

Thomsen KR, Thylstrup B, Kenyon EA, Lees R, Baandrup L, Weing SWF, Freeman TP. Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth with hazardous or harmful cannabis use) *Neuroscience and Biobehavioral Reviews* 2021;132:169-80.

Thorup AAE, Gantriis DL, Greve AN, Henriksen MT, Zahle KK, Stadsgaard H, Ellersgaard D, Burton BK, Christiani CJ, Spang K, Hemager N, Jepsen JRM, Plessen KJ, Nordentoft M, Mors O, Bliksted V. *BMC Psychiatr* 2022 Feb 9;22(1):100.

Thorup AAE, Hemager N, Søndergaard A, Gregersen M, Prøsch AK, Krantz MF, Brandt JM, Carmichael L, Melau M, Ellersgaard DV, Burton BK, Greve AN, Uddin MJ, Ohland J, Nejad AB, Johnson LK, Ver Loren van Thermaat AH, Andreassen Ak, Vedum L, Knudsen CB, Stadsgaard H, M Jepsen JR, Siebner HR, Østergaard L, Bliksted VF, Plessen KH, Mors O, Nordentoft M. The Danish High Risk and Resilience study-VIA 11: Study Protocol for the First Follow-Up of the VIA 7 Cohort -522 Children Born to Parents With Schizophrenia Spectrum Disorders or Bipolar Disorder and Controls being Re-examined for the First Time at Age 11. *Front Psychiatr* 2018 Dec;9:661. eCollection.

Thorup AA, Jepsen JR, Ellersgaard DV, Burton BK, Christiani CJ, Hemager N, Skjærbæk M, Ranning A, Spang KS, Gantriis DL, Greve AN, Zahle KK, Mors O, Plessen KJ, Nordentoft M. The Danish High Risk and Resilience Study – VIA 7 – a cohort study of 520 7-year-old children born of parents diagnosed with either schizophrenia, bipolar disorder or neither of these two mental disorders. *BMC Psychiatry* 2015;15:233.

Togning S, Catalan A, Modinos G, Kempton MJ, Bilbao A, Nelson B, Pantelis C, Riecher-Rössler A, Bressan R, Barrantes-Vidal N, Krebs MO, Nordentoft M, Ruhrmann S, Sachs G, Rutten BPF, van Os J, de Haan L, van der Gaag M, EU-GEI High Risk Study Group, McGuire P, Valmaggia LR. Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. *Schizophr Bull* 2020 Jul 8;46(4):823-33.

Tognin S, van Hell HH, Merritt K, Winter-van Rossum I, Bossong MG, Kempton MJ, Modinos G, Fusar-Poli P, Mechelli A, Dazzan P, Maat A, De Haan L, Crespo-Facorro B, Glenthøj B, Lawrie SM, McDonald C, Gruber O, van Amelsvoort T, Arango Lopez C, Kircher T, Nelson B, Galderisi S, Bressan R, Kwon JS, Weiser M, Mizrahi

R, Sachs G, Maatz A, Kahn R, McGuire P; PSYSCAN Consortium Towards Precision Medicine in Psychosis: Benefits and Challenges of Multi-Modal Multi-Center studies PSYSCAN: Translating neuroimaging findings from research into clinical practice. Bull 2019 PSYSCAN Consortium. Schizophr Bull 2020 Feb 26;46(2):432-441.

Uldall SW, Nielsen MØ, Carlsson J, Glenthøj B, Siebner HR, Madsen K, Madsen CG, Leffers AM, Nejad AB, Rostrup E. Associations of neural processing of reward with posttraumatic stress disorder and secondary psychotic symptoms in trauma-affected refugees. Eur J Psychotraumatol 2020 Mar 4;11(1):1730091 eCollection 2020.

Urbandibia-Centelles O, ...Rostrup E, ...Benedek Krisztina. Automatic continuous EEG signal analysis for diagnosis of delirium in patients with sepsis. 2021 Sep;132(9):2075-82.

Van Reenen TE, Cropley V, Fagerlund B, Wannan C, Bruggemann J, Lenroot RK, Sundram S, Weickert CS, Weickert TW, Zalesky A, Bousman CA, Pantelis C. Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders. Psychol Med 2020 Jul;50(9):1475-89.

Van Themaat AHVL, Uddin J, Christiani CJ, Hemager N, Ellersgaard D, Burton BK, Spang KS, Greve A, Gantriis D, Mors O, Throup AAE, Plessen KJ, Nordentoft M, Jepsen JRM. Odor Identification in 7-year-old Children at Familial High Risk of Schizophrenia or Bipolar Disorder – The Danish High Risk and Resilience Study VIA 7. Schizophr Res 2020;216:77-84.

Vangkilde A, Jepsen JRM, Schmock H, Olesen C, Arnasdóttir S, Baaré WFC, Plessen KJ, Didriksen M, Siebner HR, Werge T, Olsen L. Associations between social cognition, skills, and function and subclinical negative and positive symptoms in 22q11.2DS. J Neurodevelopmental Disorders 2016 Nov 16;8(42) e collection.

Veddum L, Greve An, Andreassen AK, Knudsen CB, Brandt JM, Gregersen M, Krantz MK, Søndergaard A, Ohland J, Burton BK, Jepsen JRM, Hemager N, Thorup AAE, Nordentoft M, Mors O, Bliksted V. Development of social responsiveness and theory of mind in children of parents with schizophrenia or bipolar disorder. Schizophr Res Cogn 2022 Feb 23;28:100242 eCollection Jun.

Velthorst E, EU-GEI High Risk Study (Glenthøj BY, Nordholm D, Krakauer K, Randers L, Glenthøj LB). Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Mol Psychiatr 2021 Aug;26(8):4529-43.

Vlaskamp C, Oranje B, Madsen GF, Møllegaard Jepsen JR, Durston S, Cantio C, Glenthøj B, Bilenberg N. Auditory processing in autism spectrum disorder: Mismatch negativity deficits. Autism Res 2017;19(11):1857-65.

Waller KL, Mortensen EL, Avlund K, Fagerlund B, Lauritzen M, Gammeltoft S, Jennum P. Melatonin and cortisol profiles in late midlife and their association with age-related changes in cognition. Nat Sci Sleep 2016 (21);8:47-53.

Waller KL, Mortensen EL, Avlund K, Osler M, Fagerlund B, Lauritzen M, Jennum P. Subjective sleep quality and daytime sleepiness in late midlife and their association with age-related changes in cognition. Sleep Med 2016 Jan;17:165-73.

Waser M, Lauritzen MJ, Fagerlund B, Osler M, Mortensen EL, Sørensen HBD, Jennum P. Sleep efficiency and neurophysiological patterns in middle-aged men are associated with cognitive change over their adult life course. *J Sleep Res* 2019 Aug;28(4):e12793.

Wenneberg C, Glenthøj BY, Glenthøj LB, Fagerlund B, Krakauer K, Kristensen TD, Hjorthøj C, Edden RAE, Broberg BV, Bojesen KB, Rostrup E, Nordentoft M. Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. *Eur Psychiatr* 2020 Aug 7;63(1):e83. Doi:10.1192/j.eurpsy.2020.77.

Wenneberg C, Nordentoft M, Rostrup E, Glenthøj LB, Bojesen KB, Fagerlund B, Hjorthøj C, Krakauer K, Kristensen TD, Schwartz C, Edden RAE, Broberg BV, Glenthøj BY. Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-High Risk for Psychosis and the association With Clinical Symptoms and Cognition: *Biol Psychiatry Cogn Neurosci Neuroimaging* 2020 Jun;5(6):569-79.

Wenneberg C, Glenthøj BY, Hjorthøj C, Zingenberg FJB, Glenthøj LB, Rostrup E, Broberg BV, Nordentoft M. Supplementary data for a focused review and meta-analysis of <sup>1</sup>H-MRS studies on cerebral glutamate and GABA levels in high-risk of psychosis states. *Data Brief. eCollection* 2020 Feb.

Wenneberg C, Glenthøj BY, Hjorthøj C, Zingenberg FJB, Glenthøj LB, Rostrup E, Broberg BV, Nordentoft M. Cerebral glutamate and GABA levels in high-risk of psychosis states: a focused review and meta-analysis of <sup>1</sup>H-MRS studies. *Schizophr Res* 2020 Jan;215:38-48.

Witten LM, Bastlund J, Glenthøj B, Bundgaard C, Steiniger-Brach B, Mørk A, Oranje B. Comparing pharmacological modulation of sensory gating in healthy humans and rats: The effects of reboxetine and haloperidol. *Neuropsychopharmacol* 2016 Jan;41(2):638-45.

Witten LM, Oranje B, Mørk A, Steiniger-Brach B, Glenthøj BY, Bastlund JF. Auditory sensory processing deficits in sensory gating and mismatch negativity-like responses in the social isolation rat model of schizophrenia. *Behav Brain Res* 2014;266:85-93.

Wulff S\*, Nielsen MØ\*, Rostrup E, Svarer C, Jensen LT, Pinborg L, Glenthøj BY. The relation between Dopamine D2 Receptor Blockade and the Brain Reward system – A Longitudinal Study of First-Episode Schizophrenia Patients. \* shared first authorship. *Psychol Med* 2020 Jan;50(2):220-8.

Wulff S, Pinborg LH, Svarer C, Jensen LT, Nielsen MØ, Allerup P, Bak B, Rasmussen H, Frandsen E, Rostrup E, Glenthøj BY. Striatal D2/3 Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate with Treatment Outcome. *Schizophr Bull* 2015 Sep;41(5):1143-52.

Yri HM, Fagerlund B, Forchhammer HB, Jensen RH. Cognitive function in idiopathic intracranial hypertension: A prospective case-control study. *BMJ Open* 2014;4(4):e004376.

Zarnani K, Smith SM, Alfaro-Almagro F, Fagerlund B, Lauritzen M, Rostrup E, Nichols TE. Discovering correlates of age-related decline in a healthy late-midlife male birth cohort. *Aging (Albany NY)* 2020 Sep 10;12(17):16709-43. Free PMC article.

Zarnani K, Nichols TE, Alfaro-Almagro F, Fagerlund B, Lauritzen M, Rostrup E, Smith SM. Discovering markers of a healthy aging: a prospective study in a Danish male birth cohort. *Aging* 2019 Aug 26;11(16):5943-74.